(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 26 September 2002 (26.09.2002)

PCT

(10) International Publication Number WO 02/074079 A2

(51) International Patent Classification7:

- (21) International Application Number: PCT/US02/07872
- (22) International Filing Date: 15 March 2002 (15.03.2002)
- (25) Filing Language:

English

A01N

(26) Publication Language:

English

(30) Priority Data:

60/276,180

15 March 2001 (15.03.2001) US

- (71) Applicant (for all designated States except US): CLEM-SON UNIVERSITY [US/US]; Office of Technology Transfer, 300 Brackett Hall, Box 345702, Clemson, SC 29634-5702 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HECKEL, David, G. [US/AU]; 8/101 Palmerston Street, Carlton, VIC 3053 (AU). GAHAN, Linda, J. [US/US]; 101 Martin Street, Clemson, SC 29631-1526 (US).
- (74) Agent: MULLINAX, J., Bennett; Dority & Manning, P.A., P.O. Box 1449, Greenville, SC 29602-1449 (US).


- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYNUCLEOTIDE ENCODING A GENE CONFERRING RESISTANCE TO BACILLUS THURINGIENSIS TOX-INS



(57) Abstract: Nucleic acid (DNA) probes are provided which will specifically identify a gene for resistance of Bt in insect populations. Sequences are identified associated with the onset of resistance to *Bacillus thuringiensis* toxins. The sequences are used as probes to monitor the presence of acquired insect resistance associated with transgenic crops.

02/074079 A2

POLYNUCLEOTIDE ENCODING A GENE CONFERRING RESISTANCE TO BACILLUS THURINGIENSIS TOXINS

10

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

The United States Government may have rights to this invention under the terms of a sponsored research agreement by the National Science Foundation, grant number MCB-9816056.

15

RELATED APPLICATIONS

This application claims the benefit of US provisional application having serial number 60/276,180 filed on March 15, 2001, and which is incorporated herein by reference.

20

25

FIELD OF THE INVENTION

This invention is directed towards the occurrence and identification of pesticide tolerance of certain insects. The invention makes use of specific polynucleotide sequences associated with the onset of resistance to *Bacillus thuringiensis* toxins which are used as probes to monitor the presence of acquired insect resistance associated with transgenic crops. The specific polynucleotide sequences are also used to monitor changes in the frequencies of alleles which confer the resistance to the toxins.

30

35

BACKGROUND OF THE INVENTION

The bacterium *Bacillus thuringiensis* (Bt) contains genes encoding insecticidal proteins. Bt proteins are toxic when ingested by susceptible insect larvae. The protein attacks the insect's midgut, causes cessation of feeding, and eventually kills the insect. Bt toxins have been produced as fermentation products of Bt cultures and used in spray formulations for crop

:00CID--W0

10

15

20

25

30

received the commence

protection. Bt genes have also been used commercially to transform crop plants; these transgenic crop plants' cells then produce the insecticidal protein which attacks susceptible insects that attempt to feed on the plant.

The general mode of action of Bt toxins is well known in the art and is described for example by Rajamohan F, Lee MK, Dean DH (1998) *Progress in Nucleic Acid Research and Molecular Biology* 60: 1-27. The protein produced by the bacterium is usually a protoxin, which itself is not toxic until it is proteolytically cleaved by the insect's own proteases. The smaller protein resulting from proteolysis is the active toxin. This toxin diffuses through the peritrophic membrane to the midgut epithelium, where it binds to one or more sites in the membrane. This initial binding step may be reversible, but eventually the toxin becomes irreversibly bound to the membrane. A conformational change occurs in the toxin, whereby membrane-spanning alpha helices are inserted into the membrane, where they aggregate and form pores. These pores disrupt the normal osmotic balance of the epithelial cells. The cells swell and lyse, leading to destruction of the midgut epithelial cell layer and eventual death of the insect.

The initial binding step is believed to be necessary for toxin action; consequently there have been many studies on binding interactions of Bt toxins and components of the midgut, described for example by Pietrantonio PV and Gill SS (1996) in *Biology of the Insect Midgut*, Chapman & Hall, London, pp 345-372. Techniques used to study binding often start with the isolation of brush border membrane vesicles (BBMVs) from the microvillar portion of columnar epithelial cells. Binding to BBMVs in suspension can be measured using labeled toxin. Alternatively, proteins can be isolated from BBMVs, separated by denaturing electrophoresis conditions, transferred to membranes, and probed with toxin. In addition, histological sections of insect midguts can be prepared and binding of labeled toxin can be visualized using microscopy.

Binding of Bt toxins to specific insect proteins can also be measured. Several proteins that interact with Bt toxins are well known in the art. Aminopeptidases exist in many different forms in insect midguts, and many of them have been shown to bind Bt toxins (Knight PJK, Knowles BH, Ellar DJ (1995) *Journal of Biological Chemistry* 270 (30): 17765-17770; Gill SS,

Cowles EA, Francis V (1995) Journal of Biological Chemistry 270 (45): 27277-27282; Luo K, Sangadala S, Masson L, Mazza A, Brousseau R, Adang MJ (1997) Insect Biochemistry and Molecular Biology 27 (8-9): 735-743). Members of the cadherin superfamily have also been shown to bind Bt toxins 5 (Vadlamudi RK, Weber E, Ji IH, Ji TH, and Bulla LA (1995) Journal of Biological Chemistry 270: 5490-5494; and Nagamatsu Y, Koike T, Sasaki K, Yoshimoto A, Furukawa Y, (1999) FEBS Letters 460: 385-390). Phosphatase enzymes have also been implicated in Bt toxin binding (Sangadala S, Walters FS, English LH, Adang MJ, (1994) Journal of Biological Chemistry 269 (13): 10 10088-10092). TPP-75, an elastase-like serine protease, binds to certain Bt toxins and causes them to precipitate (Milne RE, Pang ASD, Kaplan H (1995) Insect Biochemistry and Molecular Biology 25 (10): 1101-1114). BTR-270, a peptidoglycan, binds Cry1A toxins with high affinity (Valaitis AP, Jenkins JL, Lee MK, Dean DH, Gamer KJ (2001) Archives of Insect Biochemistry and 15 Physiology 46 (4): 186-200). Bt toxins have also been shown to bind to nonprotein components of midgut epithelial membranes. Glycolipids from Manduca sexta have been shown to bind Cry1A toxins using an overlay technique (Garczynski SF and Adang MJ (2000) in Entomopathogenic Bacteria: From Laboratory to Field Application, Kluwer Academic Publishers, 20 pp 181-197). Neutral lipids are involved in Bt toxin binding to Manduca sexta brush border membranes (Sangadala S, Azadi P, Carlson R, Adang MJ (2001) Insect Biochemistry and Molecular Biology 32 (1): 97-107). Neutral glycolipids, especially hexa- and tri-saccharylceramides, are implicated in Cry1A toxin binding in diamondback moth (Kumaraswami NS, Maruyama T, Kurabe S, Kishimoto T, Mitsui T, Hori H, (2001) Comparative Biochemistry 25 and Physiology B- Biochemistry & Molecular Biology 129 (1): 173-183).

The relationship between binding targets for Bt-toxins and susceptibility or resistance to Bt is very complicated and not completely understood at the present time. Several hundred strains of *Bacillus thuringiensis* exist, with considerable specificity toward various groups of insects. Co-evolution between the insects and Bt has resulted in specificity of the interaction between Bt-toxin and the membranes of insect gut cells. The Bt-toxin of a particular strain of *Bacillus thuringiensis* may bind to the gut of some insect larvae but not to others. Thus, the Bt-toxins may have a high specificity for a

10

15

20

25

30

small number of insect pest species while having no significant activity against beneficial insects, wildlife, or humans.

Plants transformed to carry Bt genes and express insecticidal proteins are known in the art and include potato, cotton, tomato, corn, tobacco, lettuce, and canola. Transformed plants are known in the art as reflected in US Patent Nos. 5,608,142; 5,495,071; 5,349,124; and 5,254,799, the specifications of which are incorporated in their entirety herein by reference. The use of genetically engineered plants is designed to reduce the use of broad spectrum insecticides.

There is concern that resistance may evolve to Bt toxins, whether they are applied to plants in spray formulations or the plants are genetically engineered to express them. The development of resistance to Bt-toxin expressing crops may also result in resistance to commercial formulations of fermented strains of Bt such as DIPEL® (Abbott Laboratories).

Rapid, reliable methods for broad screening to distinguish and detect the development of Bt resistance in populations of insects are needed. Heretofore, all methods require living or fresh-frozen insect larvae or preparations derived from them. The simplest methods employ bioassays on living insects, in which survivorship or larval metabolic rates are determined over time following a diet containing a specified concentration of a Bt-toxin. One such bioassay based on reduced metabolic rates after exposure to low doses of toxin mixed into artificial diet is discussed in US Patent No. 6,060,039 to Roe *et al.* which is incorporated herein by reference. Other bioassays are based on survival after exposure to a single, high diagnostic dose of toxin (for example, Diaz-Gomez O, Rodriguez JC, Shelton AM, Lagunes-T A, Bujanos-M R, (2000) *Journal of Economic Entomology* 93 (3): 963-970).

In principle, these bioassay methods can detect resistance no matter what its biochemical or physiological mechanism is. However, they require living, healthy larvae for their use, which are not always available. A more severe limitation on these methods is that, depending on the frequency of resistance genes in the populations, millions of individuals may need to be tested to detect a single resistant larva. High-level resistance to Bt is usually recessive, which means that an insect must have two copies of the resistance

DOCID: <WO_____02074079A2_1 >

15

20

25

30

gene to be resistant. To a very good approximation, the frequency of such homozygous individuals is given by the square of the frequency of the resistance allele. For example, if the resistance allele frequency is one in a thousand, the frequency of homozygous resistant individuals is one in a million. In this example, more than a million larvae would need to be screened to detect resistance.

One solution to this problem is to develop methods for detecting the resistance genes directly. In the example just given, the frequency of heterozygous carriers of one copy of the resistance allele is $2 \times 0.001 \times 0.999$ or approximately 2 in a thousand. When resistance is recessive, these individuals would not be identified by bioassay because the one resistance allele they carry is not enough to make them fully resistant. But a direct, DNA-based method for detecting the resistance allele would identify these individuals, and sample sizes on the order of a thousand, rather than a million, would suffice.

The main limitation to developing DNA-based methods for detecting resistance alleles is that, up to now, the identity of resistance-causing genes has been unknown. In spite of much work on Bt toxin mode of action, prior to the invention described herein there has not been a demonstration of which genes, when mutated, actually cause resistance. Accordingly, there is room for variation and improvement in the art of screening assays useful in detecting the presence of genes conferring Bt resistance in natural populations.

SUMMARY OF THE INVENTION

It is one aspect of one of the present inventions to provide a genetic probe to identify and monitor resistance for the Bt-toxin in target insect populations. One such insect pest is the tobacco budworm (*Heliothis virescens*) which is a major economic pest of cotton.

It is yet another aspect of one of the present inventions to develop a DNA probe and assay protocol which distinguishes between the conditions of homozygotes and heterozygotes with respect to resistance to Bt in populations of *Heliothis virescens* and other insects.

It is yet another aspect of one of the present inventions to provide a

process and useful sequences in which nucleotide probes are used to monitor the presence of acquired insect resistance associated with a transgenic crop.

It is yet another aspect of one of the present inventions to provide a process and useful nucleotide sequences which are used to monitor population changes in the frequency of alleles which are associated with the resistance to Bt toxin.

These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description and appended claims.

10

15

20

5

BRIEF DESCRIPTION OF THE DRAWINGS

A full and enabling disclosure of the present invention, including the best mode thereof, to one of ordinary skill in the art, is set forth more particularly in the remainder of the specification, including reference to the accompanying drawings.

Figure 1 is a QTL map of the Cry1Ac resistance trait on linkage group 9 of *Heliothis virescens*.

Figure 2 is a conceptual translation of HevCaLP (s1 allele and r1 allele) in alignment with BmBtR175 of *Bombyx mori* and BtR1 of *Manduca sexta*.

Figure 3 is a northern analysis of mRNA isolated from susceptible and resistant strains following probing with the gene sequences set forth herein.

Figure 4 sets forth the insertion point of the Hel-1 element in the r1 allele of HevCaLP.

Figure 5 shows the multi-copy occurrence of Hel-1 in genomic DNA of resistant and susceptible strains of *Heliothis virescens*.

BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

The accompanying sequence ID listings are identified below. The sequence listings appear following the claims and are incorporated herein by reference.

The first sequence 1 identifies SEQ ID NO: 1 which is the DNA sequence of the susceptible allele s1of HevCaLP.

Sequence 2 is the protein sequence SEQ ID NO: 2 of a conceptual

translation of allele s1 as used in the protein alignment to Bombyx and Manduca.

Sequence 3 is the DNA sequence of SEQ ID NO: 3 which is the resistant allele r1 of HevCaLP, including the Hel-1 insert and the duplicated target sequences.

Sequence 4 is the DNA insert identified as SEQ ID NO: 4 for the Hel-1 insert which does not include duplicated target sequences.

Sequence 5, having SEQ ID NO: 5, is a DNA sequence corresponding to the left LTR of the Hel-1 insert.

Sequence 6, having SEQ ID NO: 6, is a DNA sequence corresponding 10 to the right LTR of the Hel-1 insert.

Sequence 7, having SEQ ID NO: 7, is a DNA sequence of primer F1 corresponding to bases 1982 to 2001 of SEQ ID NO: 3.

Sequence 8, having SEQ ID NO: 8, is a DNA sequence corresponding to primer R2 consisting of the reverse complement of bases 4322 to 4351 of SEQ ID NO: 3.

Sequence 9, having SEQ ID NO: 9, is a DNA sequence corresponding to primer R3 consisting of the reverse complement of bases 2029 to 2052 of SEQ ID NO: 3.

20

25

15

DESCRIPTION OF THE PREFERRED EMBODIMENT

Reference now will be made in detail to the embodiments of the invention, one or more examples of which are set forth below. Each example is provided by way of explanation of the invention, not limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, can be used on another embodiment to yield a still further embodiment. Thus, it is intended that the 30 present invention cover such modifications and variations as come within the scope of the appended claims and their equivalents. Other objects, features, and aspects of the present invention are disclosed in the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only and is not

10

15

20 :

25

30

intended as limiting the broader aspects of the present invention, which broader aspects are embodied in the exemplary constructions.

In describing the various figures herein, the same reference numbers are used throughout to describe the same material, apparatus or process pathway. To avoid redundancy, detailed descriptions of much of the apparatus once described in relation to a figure is not repeated in the descriptions of subsequent figures, although such apparatus or process is labeled with the same reference numbers.

Applicants' protocols and procedures may be found in reference to "Identification of a Gene Associated with Bt resistance in Heliothis virescens" which was published in Science, volume 293, pp 857-860, on August 3, 2001; and which is incorporated herein by reference.

A resistant strain of *Heliothis virescens* was previously developed in the laboratory by selection using artificial diet containing various concentrations of Bt toxin (Gould F, Anderson A, Reynolds A, Burngarner L, Moar W (1995) *Journal of Economic Entomology* 88 (6): 1545-1559). The strain, named YHD2, is 10,000 fold more resistant to the toxin Cry1Ac and is conditioned in a large part by a single recessive gene named BtR-4 which is located in linkage group 9 of *H. virescens*. The initial localization of the resistance gene BtR-4 has been reported in the Applicants' prior publication (Heckel DG, Gahan LC, Gould F, Anderson A (1997) *Journal of Economic Entomology* 90: 75-86) and which is incorporated herein by reference.

Further localization of BtR-4 to a particular region of linkage group 9 was carried out using a total of 11 polymorphic markers spanning a length of 105 cM. The markers were scored on a segregating backcross family derived from YHD2 females crossed with susceptible males. The linkage group was scanned for quantitative trait loci (QTLs) conferring Bt resistance following the methods of Lander, ES and Botstein D (1989) *Genetics* 121: 185-193. A single, highly significant peak of the log-likelihood function indicated that the BtR-4 resistance gene is located between A14 and MPI as set forth in Fig. 1.

The cadherin superfamily was chosen as a candidate for BtR-4.

Partially degenerate oligonucleotide primers Bmtp5 and Bmtp8 as shown in Table 1 were designed based on published sequence of the BtR175 gene from Bombyx mori (GenBank Accession No AB026260, described by

15

20

25

30

Nagamatsu Y, Toda S, Koike T, Miyoshi Y, Shigematsu S, Kogure M (1998) *Bioscience, Biotechnology and Biochemistry* 62 (4): 727-734). These primers were used in the polymerase chain reaction (PCR) with cDNA prepared from midgut mRNA of larval *Heliothis virescens*. A PCR product of 334 basepairs designated Hvcad58 was amplified, cloned and sequenced using conventional methodology well-known to those skilled in the art. The sequence of Hvcad58 corresponds to bases 4279 to 4612 of SEQ ID NO: 1.

Radiolabeled Hvcad58 was used to probe Southern filters made from additional segregating backcross families for further mapping on linkage group 9. Finer scale QTL mapping in this region using 268 backcross progeny yielded a single peak of the log-likelihood function directly above the map location of Hvcad58 (Fig. 1). The data clearly indicates that the gene containing Hvcad58 is a strong candidate for the BtR-4 resistance gene.

The Hvcad58 probe was used to screen midgut cDNA libraries made from resistant (YHD2) and susceptible strains of *Heliothis virescens*. Clones recovered from these libraries were sequenced and used to design additional primers to amplify the full-length coding sequence from susceptible cDNA. In addition to the cDNA methods, a five-prime RACE (rapid amplification of cDNA ends) technique was used to complete the full sequence.

The sequencing yielded one transcript (s1) cloned from a susceptible strain as given in SEQ ID NO: 1. Conceptual translation of this transcript produced a protein product (that we have named HevCaLP, *Heliothis virescens* cadherin-like protein) of 1732 amino acids as given in SEQ ID NO: 2. HevCaLP is 70% identical to the BtR175 protein, sharing a signal sequence at the amino terminus, 11 extra-cellular cadherin-type repeats, a non-cadherin proximal membrane region, a transmembrane region, and a highly conserved cytoplasmic domain at the carboxy terminus as shown in Fig. 2. It shows somewhat less similarity to the BT-R1 protein from *Manduca sexta*, as given in GenBank Accession No. AAB33758 and reported by Vadlamudi RK, Weber E, Ji IH, Ji TH, and Bulla LA (1995) *Journal of Biological Chemistry* 270: 5490-5494. The transmembrane and cytoplasmic domains are absent from that sequence of BT-R1.

Expression of the mRNA encoding HevCaLP in susceptible and resistant larval midguts was studied using northern analysis and sequencing

10.

15

20

25

of clones from the resistant library. As shown in Fig. 3, susceptible larvae show a single transcript of 5.5 kb. YHD2 larvae show three transcripts. The sequence of the rarest (7.9 kb) is denoted as the r1 allele, and given as set forth in SEQ ID NO: 3. It is similar to the susceptible transcript except for a 2.3 kb insert denoted as Hel-1 as given in the accompanying SEQ ID NO: 4. Hel-1 shows several hallmarks of the LTR-type retrotransposons. Hel-1 has an approximately 255 nucleotide long terminal repeat (LTR) sequence at both ends and an unrelated sequence in the middle. The left LTR sequence, LTRa, is given in SEQ ID NO: 5 and the right LTR sequence, LTRb, is given in SEQ ID NO: 6. Hel-1 is flanked by an 8-nt duplication of the host sequence ACACTGCC, as shown in Fig. 4. The transcript of intermediate abundance (4.4 kb) is an abbreviated form, truncated at the second LTR of Hel-1 by a poly-A tail. The third, highly abundant transcript (2.1 kb), is truncated at the first LTR of Hel-1 by a poly-A tail.

Because of an in-frame stop codon 30 bases into the first LTR of Hel-1, conceptual translation of the three different YHD2 transcripts produces the same truncated 622-aa protein (as shown in the translation of the r1 allele in Fig. 2). Multiple stop codons in all three reading frames of the LTR follow the initial stop codon, preventing translation of a larger protein containing the carboxy-terminus of HevCaLP. Thus, the predicted protein product of the YHD2 r1 allele (if one is produced) would possess the same signal sequence as HevCaLP (possibly directing its secretion into the midgut lumen) but no predicted transmembrane domain or toxin-binding region.

Genomic Southern blots probed with the LTR region of Hel-1 show that it occurs with a copy number of 10-15 in both YHD2 and susceptible insects (Fig. 5). Insertion of this Hel-1 element into the gene encoding HevCaLP has created the novel, knockout r1 allele which confers resistance when homozygous (present in two copies in an individual insect). This insertion event could have occurred in the laboratory during the Bt-resistance selection protocol that produced YHD2, or may already have been present in the field-collected founders of the selection line. Thus it is now evident that a DNA-based method for detecting Bt resistance in *Heliothis virescens* may be devised, based on detection of the specific insertion of the Hel-1 element into the gene encoding HevCal-P, producing the r1 allele.

20

25

To illustrate detection of the r1 allele, a PCR assay was designed using two primers flanking the insertion point (F1 and R2) and a third (R3) internal to the left LTR (Fig. 4). Primer F1 consists of bases 1982 to 2001 of SEQ ID NO: 3, 5' ATA CGA GCT GAC GAC ACG CTG GGA GA 3', primer R2 5 consists of the reverse complement of bases 4322 to 4351 of SEQ ID NO: 3, 5' TCT GAG CGT AGG AGG TGT GTT GTT GAT GTC 3', and primer R3 consists of the reverse complement of bases 2029 to 2052 of SEQ ID NO: 3, 5' GCG CGA TGT GAC AGT CCG GAA CAG 3'. Primers F1 and R3 produce a 71-bp band from the r1 allele. Primers F1 and R2 amplify a 99-bp band from s1 or other susceptible alleles lacking the Hel-1 insert. Heterozygotes produce both bands. This is a marked improvement on a conventional bioassay, which would not distinguish heterozygotes from homozygous susceptibles because the resistant allele is recessive. It also confirms that the resistant strain is fixed for the r1 allele, as all YHD2 individuals examined to date have the 71-bp band only. It will be evident to those skilled in the art that the detection method for the r1 alelle is not limited to PCR with these specific primers, and that there are many other molecular methods of detecting the specific insertion of the Hel-1 element into the HevCaLP gene, based on the sequence information disclosed herein.

It is believed that the gene encoding HevCaLP is identical to BtR-4, the major resistance gene in YHD2. Recessivity of the resistant allele at BtR-4 is explained by Hel-1 inactivation of HevCaLP. HevCaLP functions as a "lethal target" of Bt-toxin, since two copies of the disrupted allele are required for 10,000-fold resistance. Heterozygotes still present a "lethal target" since they have one copy of the susceptible allele.

The normal physiological function of HevCaLP is unknown, although other members of the cadherin superfamily are involved in cell adhesion and signalling (T. Uemura (1998) Cell 93 (7): 1095-1098). Whatever its function, it is not essential for life, as YHD2 is viable and fertile under laboratory 30 conditions, despite being a "natural knockout" strain for HevCaLP. Whether its absence confers a fitness disadvantage in the field has important implications for resistance management, and this question can now be addressed with the information developed here. Target-site resistance to other insecticides usually involves modification but not knockout of the target,

10

20

25

which is generally essential for life (e.g., acetylcholinesterase for organophosphates, sodium channel for pyrethroids, GABA receptor for cyclodienes) (French-Constant RH, Pittendrigh B, Vaughan A, Anthony N (1998) Philosophical Transactions of the Royal Society of London Series B-Biological Sciences 353 (1376): 1685-1693,). However, methoprene resistance in Drosophila melanogaster provides another example of resistance by gene inactivation (Wilson TG & Ashok M, (1998) Proceedings of the National Academy of Sciences of the USA 95 (24): 14040-14044).

The present invention now makes possible the application of molecular methods to Bt-resistance monitoring. We previously estimated the frequency of YHD2-type resistant alleles in field populations of Heliothis virescens prior to widespread planting of transgenic Bt-cotton to be 0.002 (Gould F, Anderson A, Jones A, Sumerford D, Heckel DG, Lopez J, Micinski S, Leonard R, Laster M (1997) Proceedings of the National Academy of Sciences of the USA 94 (8): 3519-3523). This labor-intensive, bioassay-based estimate was derived by testing progeny of more than 1,000 field-caught males mated to YHD2 females, for alleles which would confer resistance when heterozygous with r1. Our results now suggest that this estimate covers the entire class of HevCaLP knockouts regardless of the nature of the molecular lesion, as well as other mutants preventing any expressed HevCaLP from functioning as a toxic target. Development of efficient DNA-based methods to detect these other types of mutants at BtR4 should be a high priority and is now possible with the methods described herein.

Only by monitoring allele frequencies at resistance genes like BtR-4 will it be possible to verify that the high-dose/refuge resistance management strategy for Bt-cotton mandated by the US Environmental Protection Agency (EPA) is actually working to keep resistance allele levels low. The present invention affords a new method of complying with EPA regulations which require monitoring resistance levels in Heliothis virescens. The present invention provides a nucleic acid probe that will specifically identify genes for resistance in field populations. Further, the probes and protocols set forth herein provide for a method of monitoring the population of homozygous and heterozygous resistant individuals in field populations.

Bt resistance in Heliothis virescens caused by other types of mutations

15

20

30

that inactivate the HevCaLP gene product may also be screened for using the information provided herein. Such methods may include obtaining portions of the gene or its homologues by cDNA cloning or the polymerase chain reaction, determining the DNA sequence by standard methods, and examining the sequence for the occurrence mutations that may include nucleotide substitution, insertions, or deletions. Such mutations may affect protein sequences encoded by the gene by causing amino acid substitutions, insertions, or deletions as well as incorrect intron splicing, premature chain termination due to nonsense mutations, or errors in the normal initiation or termination of the transcription or translation.

By way of example, DNA or RNA isolated from individual *Heliothis virescens* is used as the template for PCR using primers specifically designed from SEQ ID NO: 1. The PCR products are directly sequenced, or cloned and sequenced, using standard methods. The sequences are examined using commercially available computer programs well known in the art, such as the Wisconsin Genetics Computer Group package. Mutations, such as individual nucleotide substitutions, insertions, or deletions; or insertions or deletions of several nucleotides, are detected by comparison to SEQ ID NO: 1. Such mutations may alter the amino acid in the protein sequence, leading to reduced binding of Bt toxins to the HevCaLP gene product and thereby conferring resistance. Or such mutations may cause frameshifts or premature occurrence of stop codons, resulting in a truncated or absent protein that fails to bind to Bt toxins and thereby confers resistance.

In the course of this invention, an isolated nucleic acid molecule of the present invention includes a nucleic acid that is at least about 85%, preferably at least about 90%, and still more preferably at least about 95%, and even more preferably at least about 99% identical to the sequence of the susceptible allele s1 of HevCaLP. Additionally, any isolated polynucleotide or naturally occurring polynucleotide that hybridizes to the sequence set forth in SEQ ID NO: 1 at 60°C in 1X SSC will have properties useful in carrying out the present invention.

Other embodiments of the present invention include isolated nucleic acid molecules that are at least about 85%, preferably at least about 90%, still more preferably at least about 95%, and even more preferably at least about

99%, identical to the sequences set forth in SEQ ID NO: 3 and SEQ ID NO: 4.

Bt resistance in other insect species may also be screened for using the same approach. These species may contain one or more genes homologous to the *Heliothis virescens* HevCaLP gene, whose products interact with Bt toxins. Resistance in these other species can be detected by obtaining the sequence of those genes, designing PCR primers, and amplifying and sequencing DNA from individual insects collected from the field or reared in the laboratory. Examination of the sequence for inactivating mutations as described herein will detect Bt resistance in those species.

- 10. Representative sequences of HevCaLP homologues in other species and which may be used in the screening process described herein include the following:
 - 1) Manduca sexta BT-R1, GenBank Accession No. 177078, US Patent No. 5693491 (SEQ ID NO: 1) and US Patent No. 6,007,981 (SEQ ID NO: 1);
- 2) Bombyx mori BtR175, GenBank Accession No. AB026260, described by Nagamatsu Y, Toda S, Koike T, Miyoshi Y, Shigematsu S, Kogure M (1998) Bioscience, Biotechnology and Biochemistry 62 (4): 727-734;
 - 3) Pectinophora gossypiella BT-R2, GenBank Accession No. AX150183, Patent Application, International Publication No. WO01/34807 (SEQ ID NO:
- 20 1);
 - 4) Ostrinia nubilalis, GenBank Accession No. AX147201, Patent application, International Publication No. WO 01/36639 (SEQ ID NO: 1);
- 5) Helicoverpa zea, GenBank Accession No. AX147203, Patent application, International Publication No. WO01/36639 (SEQ ID NO: 3);
- Spodoptera frugiperda, GenBank Accession No. AX147205, Patent application, International Publication No. WO0/136639 (SEQ ID NO: 5); and
 Lymantria dispar BTR-CAD, GenBank Accession No. AF317621.
 - The above identified sequences and the referenced publications are all incorporated herein by reference as is set forth in their entirety.

The current methodology includes detecting resistance to *Bacillus* thuringiensis endotoxin in insect populations by screening for mutations that alter the structure or function of a protein as set forth in SEQ ID NO: 2. For the purposes of screening protocols, it is believed that using the sequence set forth in SEQ ID NO: 2 may include homologues and other species which

;DOCID: <WO_____02074079A2_I_:

10

15

20

25

30

would display at least 60% similarity to the sequence set forth in SEQ ID NO: 2. More preferably, the sequence similarity is at least about 75%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, still more preferably at least about 95%, and even more preferably at least about 99% identical to the amino acid sequence set forth in SEQ. ID. NO: 2.

Several of the mutations in other species detected by this approach may not have an obvious effect of activating the HevCaLP homologue. In that case, evidence that the mutation confers resistance may be obtained by conducting a linkage analysis and mapping the gene as described herein for Heliothis virescens. For that purpose, a strain of the species of interest with the mutation is crossed with a wild-type strain, and the F1 hybrids are intercrossed or backcrossed to one of the parental strains. The F2 or backcross progeny are tested for resistance by any of the bioassay methods described previously and well known in the art, and DNA is isolated from each individual progeny. The DNA is analyzed for the presence of the mutation, using restriction fragment polymorphism analysis, allele-specific PCR, denaturing gradient gel electrophoresis, single-stranded conformation polymorphism, denaturing high-performance liquid chromatography, or any other mutation detection system well known in the art. Evidence that the mutation confers resistance is obtained from the correlation across progeny between presence of the mutation and presence of resistance.

A straightforward extension of this method of detecting Bt- resistance is to examine the DNA sequence of genes encoding other proteins that interact with Bt toxins, including but not limited to aminopeptidases, alkaline phosphatases, elastin-like serine proteases, and peptidoglycans.

All cited references, publications, and sequence listings set forth herein are incorporated by reference in their entirety.

These and other modifications and variations to the present invention may be practiced by those of ordinary skill in the art, without departing from the spirit and scope of the present invention. In addition, it should be understood that aspects of the various embodiments may be interchanged both in whole or in part. Furthermore, those of ordinary skill in the art will appreciate that the foregoing description is by way of example only, and is not

intended to limit the invention.

DOCID: <WO____02074079A2_I_>

र महा क्यांचेत्र १००० के उक्त उन्हें के हरा

Primers Used in Determining the Structure of BtR4, the Cadherin-like Polynucleotide in Heliothis virescens

```
5'- GTR CTG ACK CTT AAY ATC CAG CCC ACK GC -3'
Bmtp 5
            5'- TAC GGG YAC RTT RTC SCG KAT GAA GTG KCC -3'
Bmtp 8
           -5'- AGC CCA CTG CAT CTA TGC ACG GCA TGT TTG A -3'
Hvtp05
            5'- CCT GAC TTC GGT CTG GTC GTC CCT GGC -3'
Hvtp08
            5'- TGT GGA GTC AGC TTC CAT AGA GTC TTG TAT CAG CGT GTA -3'
CGp1
            5'- GAT ACG CGG CCG CAG GTC AGC AGA GCT CTG TTG ATG GTG TCG
CGnotp2
            AGG GTG GAG A -3'
            5'- TAN GTT GGG TAN CGC CAG GGT TTT CCC AGT CAC -3'
T7p1
            5'- GGC CAG TGA ATT GTA ATA CGA CTC ACT ATA GGG CG -3'
T7p2
            5'- GAT AAC AAT TTC ACA CAG GAA ACA GCT ATG ACC ATG -3'
T3pl
            5'- GAA ATT AAC CAC CCT TAA AGG GAA CAA AAG CTG GAG
T3p2
            5'- GGC ACG TTT TTT TCC ACT GAC GGG GTC GTG CG -3'
CGp3
            5'- GAT ACG CGG CCG CGG GCA GTC TGA GCG TAG GAG GTG TGT TGT
Cgnotp4
            TGA T -3'
            5'- GAC GTG TGT TCG CCT GAT CCT AAC TAC T -3'
RC36T4
            5'- AGC CTC TTA AAT CCA TAG CGG TCT CCA G -3'
RC36cq5
            5'- CTG GAG ACC GCT ATG GAT TTA AGA -3'
RC36cg5+
            5'- ATG TTC GAG GTG CTG TAC CTC ACC G -3'
SC3T6
            5'- ACA CGA ACA CAG GAT CGT GGA AGT T -3'
SC3cg7
            5'- TGT ATC TTC TGG AAC TCC GGC ACT TCG AAG TC -3'
CGp5
            5'- GAT ACG CGG CCG CAT GTG ATG GTT CTG CGT GCC GAC GAT GAA
CGnotp6
            GGA CTG -3'
            5'- GCT AAG GAC CGG GAT ATT GAT GAT AGA GT -3'
Sint1
            5'- CGT GCG GGG CAG TCT GAG AGT AG -3'
Sint2
            5'- CAT ACA CGA CCG CAC'GCG CAA CG -3'
RUNI1
            5'- TGA GCG CCG AGG TGC AGG TGT AGG -3'
RUNI2
             5'- CTG TAC ACA GCC GGC ATC TCC AC -3'
Hvtp13
Hvtp14
             5"- CTG GAA GTT GAG GGT CAG CAC TCC AGT -3'
             5'- AAC CGT CGT CTG GAA GCT CT -3'
Hvtp15
Hvtp16
             5'- TCT TCG ATG CCG ATC AGA TCC GAG TC -3'
             5'- GCG GCG CCG GGC ACC AAC AAG CA -3'
Hvtp17
             5'- AAT AGA TGC TCT TAC ATA ATA CGA GTA TCT TAC -3'
HvAl1-RT
             5'- GAT ACG CGG CCG CGA GAA CTA TGA GAT GGC AGT CGA CGT GAG
 5'R5A4/8
                                            • :
             AAT A -3'
             5'- GAA CTA TGA GAT GGC AGT CGA CGT GAG AAT -3'
 HVA11F1
             5'- TTA ACT TTC GCG CAA GAT TGT TCC TAT ATG -3'
             5'- GAA CTC TGG GCT GAA GGG GGT AGC -3'
 HVA11R2
 HvAllR4
             5'- CCC GAA GTT RTT GTT ATG GTT TGC TAC TGA -3'
             5'- ATG GGC AAC GCA GTT AAC TAC CTG -3'
 USTP01
             5' -- CAT CCT CGT GAC AAT CGA CGA TGC 3'
 USTP02
             .5'- CAG ACA GAA CGA GCT CTT TGT GCA -3'
 USTP03
 F771-5Ksp1 5'- GCC GTG CAG CAG TTC GAT GAG AAG -3'
 F771-5Ksp2 5'- CTC CCA CTG TAT CAG TAG CCA TCA -3'
 738-3.4Kspl 5'- ACA ATC CTT CAG GGT TCG AGC CAT C -3'
 738-3.4Ksp2 5'- GTA CAA GAG AAA ATC GCG CGT TGC GT -3'
 738-3.4Kep3 5'- CCT GAT CAA CTG GAA CGA TGA GCT G -3'
 738-3.4Ksp4 5'- CCA AAG TCC ACG GGC GGT TGC GCA C -3'
```

TABLE 1

Primers Used in Determining the Structure of BtR4, the Cadherin-like_-Polynucleotide in Heliothis virescens (continued)

```
738-3.8sp6 5'- GTG TAA CGT AGT GTG CTC GTG TAA TGC -3'
738-C10sp8- 5'- CCG TCT GAA ACA TGT CGA AGT CAT -3'
            5'- GAG ACT AGC ACC TAC ACG GTC GCT -3'
            5'- TCC AAC GAG CTG TTC CTG CTG ACG -3'
TBR02
            5'- CAC TGT TAC TGT CAA TGT. TCG AGA -3'
CR9TBR ·
LTR-Pr1
            5'- CAC ACG TCA TCG TGC GCC CCA CCT AAG CTG -3'
            5'- CTG GCG CGA CCT CAT AGG CCG GCG CGA TGT -3'
LTR-Pr2
LTR-1.9Kspl 5'- CGA ATC AGC TGA TTC ATT GTC GCT -3'
LTR-1.9Ksp2 5'- GTA GTG TGT GAT GTG ATC CAG -3'
            5'- ATA CGA GCT GAC GAC ACG CTG GGA GAG CC -3'
Rint-Fwdl
            5'- TCT GAG CGT AGG AGG TGT GTT GAT GTC -3'
Rint-Rev2
C36RESEQ-F 5'- CCC GGC ACC GAC AAC TCC -3'
C36RESEQ-R 5'- CTC CAT GGT CGT ATG CCT TGA CAT GTA -3'
            5'- GAG ATG GCA GTC GAC GTG AGA ATA CTG A -3'
pc11Fa
            5'- CCC GTT TCG CCG TGT TCA GGA ATG TC -3'
pc12Fa
            5'- TGG TAC CTC GGT AGT TAA GCC TGG CAA T -3'
pc12Ra
            5'- GAA CAC GGC GAA ACG GGC ACC ACA GA -3'
pc13Fa
            5'- TGC CAG GCT TAA CTA CCG AGG TAC CA -3'
pc13Ra
            5'- AAC CCG CTG CAT TTG TTT AGA GTT ACA G -3'
pc14Fa
pc14Ra
            5'- CGA ACT GCT GCA CGG CGA AGA TCT CCA T -3'
            5'- TTC CTT CCA CGT CAT TGT CGC CAT ATT T -3'
Rints-F1
            5'- ATA CGA GCT GAC GAC ACG CTG GGA GA -3'
            5'- TCT GAG CGT AGG AGG TGT GTT GTT GAT GTC -3'
RintS-R2
            5'- GCG CGA TGT GAC AGT CCG GAA CAG -3'
RintR-R3
            5'- ACG CGC AAC GCG CGA TCT ACT CTT -3'
RintR-F4
```

TABLE 1

THAT WHICH IS CLAIMED IS:

- 1. An isolated polynucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 4, 7, 8 and 9.
- 2. A nucleotide sequence having at least an 85% identity of one of the sequences set forth in Claim 1.
- 3. An isolated nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 2.
- 4. Any isolated polynucleotide or naturally occurring polynucleotide that hybridizes the sequence in Claim 1 at 60°C in 1X SSC.
 - 5. An isolated polynucleotide encoding an allele of a gene which when homozygous confers resistance to *Bacillus thuringiensis* endotoxin comprising the sequence of SEQ ID NO: 3.
 - 6. A nucleotide sequence having at least an 85% identity to the sequence set forth in Claim 5.
 - 7. An isolated polynucleotide encoding a mobile genetic element capable of being inserted into the genomic DNA of insects, comprising the sequence of SEQ ID NO: 4.
 - 8. A nucleotide sequence having at least an 85% identity to the sequence set forth in Claim 7.
 - The complement of any of the sequences set forth in Claim 1.
 - 10. A method of detecting resistance to *Bacillus thuringiensis* endotoxin in *Heliothis virescens* populations by screening for the presence of mutations having a sequence selected from the group consisting of SEQ ID NO: 3 or SEQ ID NO: 4.
 - 11. A method of detecting resistance to *Bacillus thuringiensis* endotoxin in insect populations by screening for mutations that alter the structure or function of any protein encoded by the nucleotide sequence set forth in SEQ ID NO: 1.
 - 12. A method of detecting resistance to *Bacillus thuringiensis* endotoxin in insect populations by screening for mutations that alter the structure or function of any protein having at least a 60% similarity to the sequence of SEQ ID NO: 2.

- 13. A method for detecting mutations in genes from insect populations by screening for the presence of insertions of a DNA sequence set forth in Claim 8.
- 14. A process for monitoring Bt resistance associated with the presence of an r1 allele in an insect population associated with transgenic crops comprising the steps of:

obtaining DNA from an individual insect;

amplifying said DNA using primers having nucleotide sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

measuring the molecular size of said amplified DNA, thereby determining whether said individual is a susceptible, a heterozygote, or a homozygote for said r1 allele.

15. A process for determining Bt resistance in an insect species containing one or more genes homologous to the HevCaLP gene comprising the steps of:

identifying a first gene encoding a cadherin-like protein; identifying a second gene, said second gene a mutant of said first gene, said mutant gene associated with Bt resistance;

producing a set of primers for PCR amplification of a sample of DNA containing either one of said first gene or said second gene, said set of primers having at least one individual primer unique for a mutated portion of said second gene;

amplifying DNA from an insect using said set of primers; separating said amplified DNA according to size;

determining from said separated DNA whether said individual insect is a homozygote, a heterozygote, or a susceptible individual with respect to said mutant gene.




Fig. 1




Fig. 2

Charlest Edition (1) to be before 1911






Fig. 3



DOCID: <WO

5/5



11g. 5

A CONTRACTOR BOOK OF THE

1/22

SEQUENCE LISTING<110> Clemson University<120> Polynucleotide encoding a gene conferring resistance to Bacillus thuringiensis toxins<130> CXU-352-PCT<160> 9 <170> PatentIn version 3.1<210> 1<211> 5355<212> DNA<213> Heliothis virescens<220><221> CDS<222> (10)..(5208)<223>

<300><301> Linda J. Gahan and David G. Heckel<302> Identification of a gene associated with Bt resistance in Heliothis virescens<303> Science<304> 293<305> 5531<306> 857-860<307> 2001-08-03<308> GenBank AF367362<309> 2001-08-12<313> (1)..(5355)<300><308> GenBank AF367362<309> 2001-08-12<313> (1)..(5355)<400> 1 aactatgag atg gca gtc gac gtg aga ata ctg acg gca gcg gta ttg att Met Ala Val Asp Val Arg Ile Leu Thr Ala Ala Val Leu Ile ctc gct gct cat tta acg gtc gcg caa gat tgt tct tac atg gta gca 99 Leu Ala Ala His Leu Thr Val Ala Gln Asp Cys Ser Tyr Met Val Ala 15 20 25 att cct aga cca gag cga cca gat ttt cct aat caa aat ttc gaa gga . 147 Ile Pro Arg Pro Glu Arg Pro Asp Phe Pro Asn Gln Asn Phe Glu Gly 35 40 gta cca tgg agt cag aac ccc ctg tta cca gcg gag gat agg gaa gat 195 Val Pro Trp Ser Gln Asn Pro Leu Leu Pro Ala Glu Asp Arg Glu Asp 50 55 gtg tgc atg aac gcg ttc gac ccg agt gcc ttg aac ccc gtc acc gtc 243 Val Cys Met Asn Ala Phe Asp Pro Ser Ala Leu Asn Pro Val Thr Val 65 70 atc ttc atg gag gag gag atc gaa ggg gac gtg gcc att gcc agg ctt 291 Ile Phe Met Glu Glu Glu Glu Gly Asp Val Ala Ile Ala Arg Leu 80 aac tac cga ggt acc aat act ccg acc gtg gta act cca ttt aac ttt 339 Asn Tyr Arg Gly Thr Asn Thr Pro Thr Val Val Thr Pro Phe Asn Phe 95 105 · 105 100 ggt acc ttc cac ttg ttg ggg ccg gtc ata cgt agg atc ccc gag caa 387 Gly Thr Phe His Leu Leu Gly Pro Val Ile Arg Arg Ile Pro Glu Gln 115 120 ggg ggg gac tgg cat ctt gtt att acg cag agg cag gac tat gag acc 435 Gly Gly Asp Trp His Leu Val Ile Thr Gln Arg Gln Asp Tyr Glu Thr 130 135 140 ccg aac atg cag cag tat atc ttc aac gtg agg gta gaa gac gag ccc 483 Pro Asn Met Gln Gln Tyr Ile Phe Asn Val Arg Val Glu Asp Glu Pro 145 150 cag gaa gcc act gtg atg ctc atc att gtc aac att gac gac aac gct 531 Gln Glu Ala Thr Val Met Leu Ile Ile Val Asn Ile Asp Asp Asn Ala 160 170 cet ate ata cag atg tte gag cet tgt gae att eet gaa cae gge gaa 579 Pro Ile Ile Gln Met Phe Glu Pro Cys Asp Ile Pro Glu His Gly Glu 175 185 190

acg ggc acc aca gaa tgc aag tac gtg gtg agc gat gct gac ggc gag 627

Thr Gly Thr Thr Glu Cys Lys Tyr Val Val Ser Asp Ala Asp Gly Glu

2/22

			7	195		•• .			200	· ·				205			
atc Ile	agc Ser	aca Thr	cgt Arg 210	ttc Phe	atg Met	acg Thr	ttc Phe	caa Gln 215	atc Ile	gag Glu	agc Ser	gat .Asp	cga Arg 220	aac Asn	gat Asp		675
gaa Glu	gaa Glu	tat Tyr 225	Phe	gaa Glu	ctc Leu	gtc Val	aga Arg 230	gag Glu	aat Asn	att Ile	cag Gln	gga Gly 235	cag Gln	tgg Trp	atg Met	 	723
tac Tyr	gtc Val 240	cat His	atg Met	agg Arg	ctt Leu	atc Ile 245	ctc Leu	aac Asn	aaa Lys	cct Pro	ctg Leu 250	gac As <u>p</u>	tat Tyr	gag Glu	gaa Glu		771
aac Asn 255	ccg Pro	ctg Leu	cat His	ttg Leu	ttt Phe 260	aga Arg	gtt Val	aca Thr	gct Ala	ttg Leu 265	gat Asp	tcc Ser	cta Leu	cca Pro	aac Asn 270		819
gtt Val	cac His	aca Thr	gta Val	acg Thr 275	atg Met	atg Met	gtg Val	caa Gln	gta Val 280	gag Glu	aac Asn	ata Ile	gag Glu	agc Ser 285	aga Arg		867
cca Pro	cca Pro	cgg 'Arg	tgg Trp 290	Met	gag Glu	atc Ile	ttc Phe	gcc Ala 295	Val	cag Gln	cag Gln	ttc Phe	gat Asp 300	gag Glu	aag Lys		915
aca Thr	gca Ala	caa Gln 305	gcc Ala	ttc Phe	agg Arg	gtt Val	cga Arg 310	gcc Ala	atc Ile	gat Asp	gga Gly	gac Asp 315	äcg Thr	gga Gly	atc Ile		963
gat Asp	aaa Lys 320	cet Pro	att Ile	ttc Phe	tat Tyr	agg Arg 325	atc Ile	gaa Glu	act Thr	gaa Glu	gaa Glu 330	agc Ser	gag Glu	aaa Lys	gat Asp		1011
ttg Leu 335	ttc Phe	agt Ser	gtt Val	gaa Glu	aca Thr 340	ata Ile	gga Gly	Ala	ggt Gly	Arg 345	gaa Glu	ggt Gly	gct Ala	tgg Trp	ttt Phe 350		1059
aaa Lys	gtc Val	gct Ala	cca Pro	ata Ile 355	gac Asp	agg Arg	gac Asp	act Thr	cta Leu 360	gaa Glu	aag Lys	gaa Glu	gtt Val	ttc Phe 365	cac His	•	1107
gtg Val	tct Ser	cta Leu	ata Ile 370	gcg Ala	tac Tyr	aaa Lys	tat Tyr	ggc Gly 375	Asp	aat Asn	gac Asp	gtg Val	gaa Glu 380	gga Gly	agt Ser		1155
ccg Pro	tca Ser	ttc Phe 385	gag Glu	tcg Ser	aag Lys	Thr	gat Asp 390	atc Ile	gtc Val	att Ile	att Ile	gtg Val 395	aac Asn	gac Asp	gtg Val	· · · :	1203
aat Asn	gat Asp 400	cag Gln	gcg Ala	ccg Pro	gtg Val	cca Pro 405		cgt Arg	cct Pro	Ser	tac Tyr 410	tac Tyr	att Ile	gaa Glu	att Ile		1251
atg Met 415	gag Glu	gaa Glu	gct Ala	gcg Ala	atg Met 420	aca Thr	ttg Leu	aat Asn	Leu	gag Glu 425	gac Asp	ttt Phe	ggt Gly	ttc Phe	cac His 430		1299
gat Asp	aga Arg	ggt Gly	ctt Leu	ggt Gly 435	ccg Pro	cac His	gca Ala	cag Gln	tac Tyr 440	aca Thr	gtg Val	cac His	Leu	gag Glu 445	agc Ser	·	1347

														:		
															gtg Val	1395
Gly	tac Tyr	cag Gln 465	cga Arg	cag Gln	tcc Ser	ttc Phe	atc Ile 470	gtc Val	ggc	acg Thr	cag Gln	aac Asn 475	cat His	cac His	atg Met	1443
		ttt													gta Val	1491
		gac Asp													aac Asn 510	1539
		ctg Leu													gac - Asp	1587
gtg Val	cag Gln	act Thr	gtc Val 530	acc Thr	ttc Phe	aag Lys	gag Glu	acg Thr 535	gag Glu	ggc	gct Ala	ggc Gly	ttc Phe 540	cgg Arg	gtc Val	1635
gcc Ala	act Thr	gtt Val 545	ctg Leu	gca Ala	aag Lys	gac Asp	agg Arg 550	gat Asp	att Ile	gat Asp	gat Asp	aga Arg 555	gtc Val	gaa Glu	cat His	1683
		atg Met														1731
		atc Ile														1779
aac Asn	gag Glu	ctc Leu	ttt Phe	gtg Val 595	Gln	ata Ile	cga Arg	gct. Ala	gat Asp 600	gac Asp	acg Thr	ttg Leu	gga Gly	gag Glu 605	ccg Pro	1827
tat Tyr	aat Asn	acc Thr	aac Asn 610	acc Thr	gcc Ala	caa Gln	ctg Leu	gtg Val 615	ata Ile	cag Gln	ctg Leu	caa Gln	gac Asp 620	atc Ile	aac Asn	1875
aac Asn	aca Thr	cct Pro 625	cct Pro	acg Thr	ctc Leu	aga Arg	ctg Leu 630	cct Pro	cgc Arg	acg Thr	act Thr	ccg Pro 635	tca Ser	gtg Val	gaa Glu	1923
gag Glu	aac Asn 640	gtg Val	ccg Pro	gac Asp	gjà aaa	ttc. Phe 645	gtg V al	atc Ile	ccc Pro	acc Thr	gag Glu 650	ctg Leu	cac His	gcc Ala	acc Thr	1971
gac Asp 655	ccc Pro	gac Asp	acc Thr	acc Thr	gcc Ala 660	gag Glu	ctg Leu	cgc Arg	ttc Phe	agc Ser 665	atc Ile	gac Asp	tgg Trp	gac Asp	670	2019
tcc Ser	tat Tyr	gcc Ala	acc Thr	aag Lys 675	cag Gln	gga Gly	cga Arg	gat Asp	gct Ala 680	gat Asp	gct Ala	gag Glu	gag Glu	ttt Phe 685	gtt Val	2067

									-4122	1						
aat Asn	tgt Cys	ata Ile	gaa Glu 690	atc	gag Glu	acg Thr	gta Val	tac Tyr 695	ccg Pro	aac Asn	ttg Leu	aac Asn	gac Asp 700	cga Arg	ggc Gly	2115
acc Thr	gcc Ala	atc Ile 705	ggc Gly	cgc Arg	gtg Val	gtg Val	gtt Val 710	Arg	gag Glu	atc Ile	cgg Arg	gaa Glu 715	cac His	gtc Val	acc Thr	2163
atc Ile	gac Asp 720	tac Tyr	gag Glu	atg Met	ttc Phe	gag Glu 725	Val	ctg Leu	tac Tyr	ctc Leu	acc Thr 730	gtc Val	agg Arg	gtc Val	acg Thr	2211
gat Asp 735	ctc Leu	aac :Asn	acg Thr	gtc Val	att Ile 740	gga Gly	gac :Asp	gac Asp	tat Tyr	gat Asp 745	ata Ile	tca Ser	aca Thr	ttc Phe	acg Thr 750	2259
atc Ile	att Ile	ata Ile	ata Ile	gac Asp 755	atg Met	aac Asn	gac Asp	aac Asn	cct Pro 760	ccg Pro	ctg Leu	tgg Trp	gtg Val	gaa Glu 765	Gly -	2307
acg Thr	ctg Leu	acg Thr	cag Gln 770	gag Glu	ttc Phe	cgc Arg	gtg Val	cga Arg 775	gag Glu	gtc Val	gcc Ala	gcc Ala	tcg Ser 780	gga Gly	gtt Val	2355
gtt Val	ata Ile	gga Gly 785	tcc Ser	gta Val	ctc Leu	gcc Ala	act Thr 790	gat Asp	atc Ile	gac Asp	gga Gly	cct Pro 795	ctt Leu	tat Tyr	aat Asn	2403
caa Gln	gtg Val 800	cgg Arg	tat Tyr	acc Thr	atc Ile	act Thr 805	cct Pro	aga Arg	tta Leu	gat Asp	act Thr 810	cca Pro	gaa Glu	gac Asp	cta Leu	2451
gtg Val 815	gag Glu	atc Ile	gac Asp	ttc Phe	aat Asn 820	tcg Ser	ggt Gly	cag Gln	atc Ile	tca Ser 825	gtg Val	aag Lys	aag Lys	cac His	cag Gln 830	2499
gcc Ala	atc Ile	gac Asp	gcg Ala	gac Asp 835	gag Glu	ccg Pro	ccg Pro	cgc Arg	cag Gln 840	cac His	ctc Leu	tac Tyr	tac Tyr	acc Thr 845	Val	2547
gtc Val	gcc Ala	agc Ser	gac Asp 850	aag Lys	tgc Cys	gac Asp	ctg Leu	ctc Leu 855	tct Ser	gtc Val	gac Asp	gtg Val	tgt Cys 860	ccg Pro	cct Pro	2595
gat Asp	cct Pro	aac Asn 865	tac Tyr	ttc Phe	aac Asn	aca Thr	ccg Pro 870	gga Gly	gac Asp	ata Ile	acg. Thr	atc Ile 875	cac His	ata Ile	aca Thr	2643
gac Asp	acg Thr 880	aac Asn	aac Asn	agg Arg	gtg Val	cct Pro 885	cga Arg	gtg Val	gaa Glu	gag Glu	gac Asp 890	aag Lys	ttc Phe	gag Glu	gaa Glu	2691
att Ile 895	gtc Val	tat Tyr	atc Ile	Tyr	gag Glu 900	ggc	gcg Ala	gag Glu	gac Asp	gga Gly 905	Glu	cac His	gtc Val	gtg Val	cag Gln 910	2739
ctc Leu	ttc Phe	gcc Ala	agc Ser	gat Asp 915	ctg Leu	gat Asp	aga Arg	gat Asp	gaa Glu 920	atc Ile	tac Tyr	cac His	aaa Lys	gtg Val 925	agc Ser	2787
tac	cag	atc	aac	tac	gcg	atc	aac	cct	cgt	ctc	cgc	gac	ttc	ttc	gag - · ·	2835

									5/22	1						
Ty	c Gln	Ile	Asn 930	Tyr	Ala	Ile	Asn	Pro 1 935	Arg :	Leu 1	Arg 1	_	Phe Pl	ne Gl	u:	٠.
gta Val	a gac L Asp	ctg Leu 945	Glu	acc Thr	ggc	ctg Leu	gtg Val 950	tac q Tyr '	gtc a Val a	aac a Asn <i>I</i>	Asn 1	acg g Thr A	icc go la G	gg ga ly Gl	g u	2883
aag Lys	g ctc s Leu 960	Asp	cgg Arg	gac Asp	ggc Gly	gat Asp 965	gaa Glu	ccc a	acg (Thr 1	His A	egg a Arg 1 970	atc t [le F	tc tt he Ph	c aa ne As	c. n	2931
gtt Val 975	l Ile	gat Asp 	aac Asn	ttc Phe	tat Tyr 980	gjå aaa	gaa Glu	gga g Gly 1	Asp (ggc a Gly 7 985	aac o Asn <i>P</i>	egg a	ac ca sn Gl	ng ga In As 99	p	2979
ga <u>c</u> Glu	g aca ı Thr	caa Gln	gtg Val	tta Leu 995	gtg Val	gtg Val	ctg Leu	Leu A	gac Asp 1000	atc Ile	aac Asn	gac Asp	aac t Asn T	at yr .005	ccg Pro	3027
	g ctg i Leu			Gly	cto Leu	tca Ser	tgg Trp	gat Asp 1015	Ιle	c tct e Ser	gag Glu	Gly	ttg Leu 1020	cta Leu		3072
Glr	ggt Gly	gtc Val	cgt Arg 1025	Val	acc Thr	cca Pro	gat Asp	atc Ile 1030	Phe	gcc Ala	ccg Pro	gac Asp	cgc Arg 1035	gac Asp		3117
	ccc Pro			Asp	aac Asn	tcc Ser	cgc	gtg Val 1045	Ala	j tac Tyr	gac Asp	atc Ile	gtc Val 1050	Ser		3162
	tcg Ser			Asp				aca Thr 1060	Leu	cct Pro				acc Thr		3207
	atc Ile			Glu	aag Lys	gac Asp	agg Arg	ggc Gly 1075	ato Ile	qaA :	cag Gln	act Thr	gga Gly 1080	gag Glu		3252
_	gag Glu	•	_	Met	gat Asp	tta Leu	aga Arg	ggc Gly 1090	Туг	tgg Trp	ggc	act Thr	tat Tyr 1095	Glu		3297
ata Ile	cat His	gta Val	aag Lys 1100	Ala	tac Tyr	gac Asp	cat His	gga Gly 1105	Val	cct Pro	caa Gln	agg Arg	att Ile 1110	Ser		3342
tac Tyr	gag Glu	aag Lys	tac Tyr 1115	Pro	cta Leu	gtt Val	att Ile	aga Arg 1120	Pro	tac Tyr	aac Asn	ttc Phe	cac His 1125	_		3387
cct Pro	gtg Val	ttc Phe	gtg Val 1130	Phe	Pro	caa Gln	cct Pro	gga Gly 1135	Met	act Thr	atc Ile	aga Arg	ctc Leu 1140	gcg		3432
aag Lys	gag Glu	cga Arg	gca Ala 1145	Val	gtg	aac Asn	gga	gtg Val 1150	Leu	gcg Ala	aca Thr	gtg Val	gac Asp 1155	ggc		3477
gag Glu	ttc Phe	ctc Leu	gag Glu	çga Arg	ata Ile	gtc Val	gcc Ala	acc Thr	gac Asp	gag Glu	gat Asp	ggc Gly	tta Leu	cac His		3522

		•	0,22		
	1160		1165	1170	•
				t gat gag gcg p Asp Glu Ala 1189	
				c ttg ggt gcg n Leu Gly Ala 1200	Leu
				a gag ttt cag g Glu Phe Gln 121	Val
				t ggt cca agg o Gly Pro Arg 1230	
				t acg cag gga o Thr Gln Gly 124	
cct gtg ttc Pro Val Phe				t ttt atc gag a Phe Ile Glu 1260	
				t ctc gcc aag o Leu Ala Lys 1279	Asp
				c gac acc tat s Asp Thr Tyr 1290	Tyr
				t gcg gtg gac e Ala Val Asp 1309	
cag tcc aac Gln Ser Asn			acg cca ct	g gag cgc gcg u Glu Arg Ala 1320	Glu
				c gac tcg ccc r Asp Ser Pro 133!	Ser
				t gtt act gtc r Val Thr Val 1350	Asn
	Ala Asn F	ro Arg Pro		g agc gct ctg n Ser Ala Leu 136	
aca gcc ggc Thr Ala Gly	atc tcc a Ile Ser T 1370	icc ctc gac Thr Leu Asp	acc atc aa Thr Ile As 1375	c aga ggt ctg n Arg Gly Leu 1380	cta 4152 Leu)
Thr Leu His	Ala Thr E	lis Ser Glu	Gly Leu Pr	t gtg acc tac o Val Thr Tyr 139	acg 4197 Thr

Cto Lev	g gta Val	caa Gln	gac Asp 1400	Ser	atg Met	gaa Glu	gct Ala	gac Asp 1405	Ser	aca Thr	ctg Leu	.caa .Gln	gct Ala 1410	Val		4242
Glr	gag Glu	aca Thr	gcc Ala 1415	Phe	aac Asn	ttg Leu	aac Asn	ect Pro 1420	Gln	act Thr	gga Gly	gtg Val	ctg Leu 1425	Thr		4287
cto	aac Asn	ttc Phe	cag Gln 1430	Pro	aca Thr	gca Ala	tet Ser	atg Met 1435	His	ggc	atg Met	ttt Phe	gag Glu 1440	Phe	•	4332
gat Asp	gtg Val	atg Met	gct Ala 1445	Thr	gat Asp	aca Thr	gtg Val	gga Gly 1450	Glu	acc Thr	gcg Ala	cgc Arg	acc Thr 1455	Glu		4377
gtg Val	aag L ys	gtg Val	tac Tyr 1460	Leu	ata Ile	tcc Ser	gac Asp	cgc Arg 1465	Asn	aga Arg	gtg Val	ttc Phe	ttc Phe 1470	Thr		4422
ttc Phe	atg Met	aac Asn	acg Thr 1475	ctt Leu	gaa Glu	gaa Glu	gtc Val	gaa Glu 1480	Pro	aat .Asn	gaa Glu	gat Asp	ttc Phe 1485	ata Ile	•	4467
gcg Ala	gag Glu	aca Thr	ttt Phe 1490					ggc Gly 1495		cgg Arg	tgc Cys	aac Asn	atc 1le 1500	gac Asp		4512
cag Gln	gcg Ala	ctg Leu	ccc Pro 1505	gcc Ala	agc Ser	gac Asp	ccc Pro	gcc Ala 1510	Thr	ggc	gcc Ala	gcc Ala	agg Arg 1515	gac Asp		4557
gac Asp	cag Gln	acc Thr	gaa Glu 1520	gtc Val	agg Arg	gca Ala	cac His	ttc Phe 1525					ctg Leu 1530	cct Pro		4602
			gag Glu 1535		atc Ile	gaa Glu	caa Gln	tta Leu 1540	cgc Arg	ggc Gly	aac Asn	ccg Pro	acc Thr 1545	cta Leu		4647
			atc Ile 1550	cag Gln	aac Asn	gcc Ala	Leu	cag Gln 1555	Glu	gag Glu	aac Asn	ctg Leu	Asn			4692
gcc Ala	gac Asp	Leu	ttc Phe 1565	acg Thr	gly ggc	gag Glu	act Thr	ccc Pro 1570	Ile	ctg Leu	ggc	ggc	gag Glu 1575	gcg Ala		4737
cag Gln	gcg Ala	Arg	gcg Ala 1580	Val	Tyr	Ala	Leu	gcg Ala 1585	Ala	gtg Val	gcg Ala	Ala	gcg Ala 1590	ctc Leu	. •	4782
gcg Ala	ctg Leu	Leu	tgc Cys 1595	Val	gtg Val	Leu	Leu	ata Ile 1600	Leu	Phe	Phe	Ile	agg Arg :1605	Thr	•	4827
agg Arg	gcc Ala	Leu	aac Asn 1610	cgt Arg	cgc Arg	ctg Leu	Glu	gcc Ala 1615	cta Leu	tcc Ser	atg Met	Thr	aag Lys 1620	Tyr		4872

Ser Ser Gln	gac tca Asp Ser 1625	gga cto Gly Leu	Asn .	cgc gtg Arg Val 1630	ggt ctg Gly Let	gcg Ala	gcg Ala 1635	
ggc acc aac Gly Thr Asn	aag cac Lys His 1640	gcg gtg Ala Val	. Glu	ggc tcc Gly Ser 1645	aac ccc	atc Ile	tgg Trp 1650	aac Asn
gaa act ctt Glu Thr Leu	aag gca Lys Ala 1655	ccg gac Pro Asp	Phe I	gat gct Asp Ala 1660	ctt ago Leu Ser	Glu	cag Gln 1665	tcg Ser
tac gac tcg Tyr Asp Ser	ggt ctg Gly Leu 1670	atc ggc	Ile (gaa gac Glu Asp 1675	ttg ccg	Gln	ttc Phe 1680	agg Arg
aac gac tac Asn Asp Tyr	ttc ccg Phe Pro 1685	cct gac Pro Asp	Glu (gag agc Glu Ser 1690	tcc atg Ser Met	Arg	gga Gly 1695	gtc Val –
gtc aat gaa Val Asn Glu	cac atg His Met 1700	cct gga Pro Gly	Ala A	aat tca Asn Ser 1705	gta gca Val Ala	Asn	cat His 1710	aac Asn
aat aac ttc Asn Asn Phe	ggg ttc Gly Phe 1715	aac gct Asn Ala	Thr I	ccc ttc Pro Phe 1720	agc cca Ser Pro	Glu	ttc Phe 1725	gcg Ala
aac tcg cag Asn Ser Gln	ctc agg Leu Arg 1730	aga taa Arg	aacat	ttatag ta	atttttta	t ata	atatt	at
aaagaagtga	tataacgca	c taaaat	ttac o	ctataagta	at atatt	gaagt	gtaa	gatact
aaagaagtga								•
	aagagcatc	t atttt	ttac o	caccagaca	aa taaaa	acttt	ataa	aag
cgtattatgt a	aagagcatc 1> 1732<	t attttt 212> PR'	ttac o	caccagaca	aa taaaa chis vir	acttt escen:	ataa 3<400	aag > 2
cgtattatgt a	aagagcatc l> 1732< Asp Val 5	t attttt 212> PR Arg Ile	ttac o T<213; Leu Th	Heliot Heliot Ala Al 10 78 Ser Ty	aa taaaa :his vir la Val L	acttt escens	ataa 3<400 Leu 15	aag > 2 Ala
cgtattatgt (210> 2<21) Met Ala Val	aagagcatc 1> 1732< Asp Val 5 Thr Val 20	t attttt 212> PR Arg Ile : Ala Gln :	T<213; Leu Th Asp Cy 25	Heliot Ir Ala Al 10 VS Ser Ty	his vir la Val L	escenseu Ile al Ala 30	ataa 3<400 E Leu 15	aag > 2 Ala Pro
cgtattatgt (200 2<21) Met Ala Val Ala His Leu Arg Pro Glu	aagagcatc 1> 1732< Asp Val 5 Thr Val 20 Arg Pro	t attttt 212> PR Arg Ile : Ala Gln :	ttac of T<213; Leu Th Asp Cy 25 Pro As	Heliot Ir Ala Al 10 Vs Ser Ty 5	this virta val Lor Met Valen Phe G	escenseu Ile al Ala 30	ataa 3<400 E Leu 15 A Ile	aag > 2 Ala Pro
cgtattatgt a <210> 2<21: Met Ala Val 1 Ala His Leu Arg Pro Glu 35 Trp Ser Gln	Asp Val 5 Thr Val 20 Arg Pro 2	t attttt 212> PR Arg Ile : Ala Gln : Asp Phe : Leu Leu !	T<213; Leu Th Asp Cy 25 Pro As	Heliot Ir Ala Al 10 ys Ser Ty 5	this viria Val La Val Val La V	escenseu Ile al Ala 30 lu Gly	ataa 3<400 E Leu 15 Ile Val	aag > 2 Ala Pro Pro

- Arg Gly Thr Asn Thr Pro Thr Val Val Thr Pro Phe Asn Phe Gly Thr
 100 105 110 -
- Phe His Leu Leu Gly Pro Val Ile Arg Arg Ile Pro Glu Gln Gly Gly 115 120 125
- Asp Trp His Leu Val Ile Thr Gln Arg Gln Asp Tyr Glu Thr Pro Asn 130 135 140
- Met Gln Gln Tyr Ile Phe Asn Val Arg Val Glu Asp Glu Pro Gln Glu 145 150 155 160
- Ala Thr Val Met Leu Ile Ile Val Asn Ile Asp Asp Asn Ala Pro Ile 165 170 175
- Ile Gln Met Phe Glu Pro Cys Asp Ile Pro Glu His Gly Glu Thr Gly
 180 185 190
- Thr Thr Glu Cys Lys Tyr Val Val Ser Asp Ala Asp Gly Glu Ile Ser 195 200 205
- Thr Arg Phe Met Thr Phe Gln Ile Glu Ser Asp Arg Asn Asp Glu Glu 210 215 220
- Tyr Phe Glu Leu Val Arg Glu Asn Ile Gln Gly Gln Trp Met Tyr Val 225 230 235 240
- His Met Arg Leu Ile Leu Asn Lys Pro Leu Asp Tyr Glu Glu Asn Pro 245 250 255

Agranda are

- Leu His Leu Phe Arg Val Thr Ala Leu Asp Ser Leu Pro Asn Val His
 260 265 270
- Thr Val Thr Met Met Val Gln Val Glu Asn Ile Glu Ser Arg Pro Pro 275 280 285
- Arg Trp Met Glu Ile Phe Ala Val Gln Gln Phe Asp Glu Lys Thr Ala 290 295 300
- Gln Ala Phe Arg Val Arg Ala Ile Asp Gly Asp Thr Gly Ile Asp Lys 305 310 315 320
- Pro Ile Phe Tyr Arg Ile Glu Thr Glu Glu Ser Glu Lys Asp Leu Phe 325 330 335

- Ser Val Glu Thr Ile Gly Ala Gly Arg Glu Gly Ala Trp Phe Lys Val 340 345 350
- Ala Pro Ile Asp Arg Asp Thr Leu Glu Lys Glu Val Phe His Val Ser 355 360 365
- Leu Ile Ala Tyr Lys Tyr Gly Asp Asn Asp Val Glu Gly Ser Pro Ser 370 375 380
- Phe Glu Ser Lys Thr Asp Ile Val Ile Ile Val Asn Asp Val Asn Asp 385 390 395 400
- Gln Ala Pro Val Pro Phe Arg Pro Ser Tyr Tyr Ile Glu Ile Met Glu 405 410 415
- Glu Ala Ala Met Thr Leu Asn Leu Glu Asp Phe Gly Phe His Asp Arg
 420 425 430
- Gly Leu Gly Pro His Ala Gln Tyr Thr Val His Leu Glu Ser Ile Ser 435 440 445
- Pro Ala Gly Ala His Glu Ala Phe Tyr Ile Ala Pro Glu Val Gly Tyr 450 455 460
- Gln Arg Gln Ser Phe Ile Val Gly Thr Gln Asn His His Met Leu Asp 465 470 475 480
- Phe Glu Val Pro Glu Phe Gln Lys Ile Gln Leu Arg Ala Val Ala Ile 485 490 495
- Asp Met Asp Asp Pro Arg Trp Val Gly Ile Ala Ile Ile Asn Ile Asn 500 505 510
- Leu Ile Asn Trp Asn Asp Glu Leu Pro Ile Phe Glu His Asp Val Gln 515 520 525
- Thr Val Thr Phe Lys Glu Thr Glu Gly Ala Gly Phe Arg Val Ala Thr
 530 540
- Val Leu Ala Lys Asp Arg Asp Ile Asp Asp Arg Val Glu His Ser Leu 545 550 560
- Met Gly Asn Ala Val Asn Tyr Leu Ser Ile Asp Lys Asp Thr Gly Asp 565 570 575

- Ile Leu Val Thr Ile Asp Asp Ala Phe Asn Tyr His Arg Gln Asn Glu
 580 585 590
- Leu Phe Val Gln Ile Arg Ala Asp Asp Thr Leu Gly Glu Pro Tyr Asn 595 600 605
- Thr Asn Thr Ala Gln Leu Val Ile Gln Leu Gln Asp Ile Asn Asn Thr 610 615 620
- Pro Pro Thr Leu Arg Leu Pro Arg Thr Thr Pro Ser Val Glu Glu Asn 625 630 635 640
- Val Pro Asp Gly Phe Val Ile Pro Thr Glu Leu His Ala Thr Asp Pro 645 650 655
- Asp Thr Thr Ala Glu Leu Arg Phe Ser Ile Asp Trp Asp Thr Ser Tyr 660 665 670
- Ala Thr Lys Gln Gly Arg Asp Ala Asp Ala Glu Glu Phe Val Asn Cys 675 680 685
- Ile Glu Ile Glu Thr Val Tyr Pro Asn Leu Asn Asp Arg Gly Thr Ala
 690 695 700
- Ile Gly Arg Val Val Val Arg Glu Ile Arg Glu His Val Thr Ile Asp 705 710 715 720
- Tyr Glu Met Phe Glu Val Leu Tyr Leu Thr Val Arg Val Thr Asp Leu 725 730 735
- Asn Thr Val Ile Gly Asp Asp Tyr Asp Ile Ser Thr Phe Thr Ile Ile 740 745 750
- Ile Ile Asp Met Asn Asp Asn Pro Pro Leu Trp Val Glu Gly Thr Leu
 755 760 765
- Thr Gln Glu Phe Arg Val Arg Glu Val Ala Ala Ser Gly Val Val Ile 770 775 780
- Gly Ser Val Leu Ala Thr Asp Ile Asp Gly Pro Leu Tyr Asn Gln Val 785 790 795 800
- Arg Tyr Thr Ile Thr Pro Arg Leu Asp Thr Pro Glu Asp Leu Val Glu 805 810 815
- Ile Asp Phe Asn Ser Gly Gln Ile Ser Val Lys Lys His Gln Ala Ile

820

ومستورة ولتعادرون

825

830

Asp Ala Asp Glu Pro Pro Arg Gln His Leu Tyr Tyr Thr Val Val Ala -- 835 840 845

Ser Asp Lys Cys Asp Leu Leu Ser Val Asp Val Cys Pro Pro Asp Pro 850 855 860

Asn Tyr Phe Asn Thr Pro Gly Asp Ile Thr Ile His Ile Thr Asp Thr 865 870 875 880

Asn Asn Arg Val Pro Arg Val Glu Glu Asp Lys Phe Glu Glu Ile Val 885 890 895

Tyr Ile Tyr Glu Gly Ala Glu Asp Gly Glu His Val Val Gln Leu Phe 900 905 910

Ala Ser Asp Leu Asp Arg Asp Glu Ile Tyr His Lys Val Ser Tyr Gln 915 920 925

Ile Asn Tyr Ala Ile Asn Pro Arg Leu Arg Asp Phe Phe Glu Val Asp 930 935 940

Leu Glu Thr Gly Leu Val Tyr Val Asn Asn Thr Ala Gly Glu Lys Leu 945 950 955 960

Asp Arg Asp Gly Asp Glu Pro Thr His Arg Ile Phe Phe Asn Val Ile 965 970 975

April Barrell

Asp Asn Phe Tyr Gly Glu Gly Asp Gly Asn Arg Asn Gln Asp Glu Thr 980 985 990

Gln Val Leu Val Val Leu Leu Asp Ile Asn Asp Asn Tyr Pro Glu Leu 995 1000 1005

Pro Glu Gly Leu Ser Trp Asp Ile Ser Glu Gly Leu Leu Gln Gly 1010 1015 1020

Val Arg Val Thr Pro Asp Ile Phe Ala Pro Asp Arg Asp Glu Pro 1025 1030 1035

Gly Thr Asp Asn Ser Arg Val Ala Tyr Asp Ile Val Ser Leu Ser 1040 1045 1050

Pro Thr Asp Arg Asp Ile Thr Leu Pro Gln Leu Phe Thr Met Ile

Thr	Ile 1070		Lys	Asp	Arg	Gly 1075		Asp	Gln	Thr	Gly 1080	Glu	Leu	Glu -
Thr	Ala 1085		Asp	Leu	Arg	Gly 1090	Tyr	Trp	Gly	Thr	Туг 1095		lle	His
Val	Lys 1100		Tyr	Asp	His	Gly 1105	Val	Pro	Gln	Arg	Ile 1110	Ser	Tyr	GĨu
Lys	Tyr 1115		Leu	Val	Ile	Arg 1120	Pro	Tyr	Asn	Phe	His 1125	Asp	Pro	Val
Phe	Val 1130		Pro	Gln	Pro	Gly 1135	Met	Thr	Ile	Arg	Leu 1140	Ala	Lys	Glu
Arg	Al:a 1145		Val	Asn	Gly	Val 1150	Leu	Ala	Thr	Val	Asp 1155	Gly	Glu	Phe
Leu	Glu 1160	Arg	Ile	Val	Ala	Thr 1165		Glu	Asp	Gly	Leu 1170	His.	Ala	Gly
Val	Val 1175	Thr	Phe	Ser	Ile	Ser 1180	Gly	Asp	Asp	Glu	Ala 1185	Leu	Gln	Tyr
Phe	Asp 1190	Val	Phe	Asn	Asp	Gly 1195	Val	Asn	Leu	Gly	Ala 1200	Leu	Thr	Ile
Thr	Gln 1205	Leu	Phe	Pro	Glu	Asp 1210	Phe		Glu	Phe	Gln 1215	Val	Thr	Ile
	Ala 1220					Thr 1225					Arg 1230		Thr	Asp
Cys	Thr 1235	Ile	Thr	Val	Val	Phe 1240	Val	Pro	Thr	Gln	Gly 1245	Glu	Pro	Val
Phe	Glu 1250	Thr	Ser	Thr	Tyr	Thr 1255	Val	Ala	Phe	Ile	Glu 1260	Lys	Asp	Ala
Gly	Met 1265	Glu	Glu	Arg	Ala	Thr 1270	Leu	Pro	Leu	Ala	Lys 1275	Asp	Pro	Arg
Asn	Ile 1280	Met	Cys	Glu	Asp	Asp 1285	Сув	His	Asp	Thr	Tyr 1290	Tyr		Ile

Val	Gly 1295		Asn		Met	Gly 1300		Phe	Ala	Val	Asp 1305	Pro	Gln	Ser
Asn	Glu 1310	Leu	Phe	Leu	Leu	Thr 1315		Leu	Glu	_	Ala 1320		Gln	Glu
Thr	His 1325		Leu			Gly 1330			Asp	Ser		Ser	Pro	Ala
Ala	Val	Leu	Gln	Ala		Thr 1345					Val 1350°		Val	Arg
Glu	Ala 1355	Asn	Pro	Arg	Pro	Val 1360		Gln	Ser		Leu 1365	Tyr	Thr	Ala
Gly	Ile 1370	Ser	Thr	Leu		Thr 1375	Ile	Asn	Arg	Gly	Leu 1380		Thr	Lėu
His	Ala 1385	Thr	His	Ser		Gly 1390	Leu	Pro	Val	Thr	Tyr 1395	Thr	Leu	Val
Gln	Asp 1400		Met	Glu		Asp 1405		Thr	Leu	Gln	Ala 1410	Val	Gjn	Glu
Thr	Ala 1415	Phe	Asn	Leu	Asn	Pro 1420	Gln	Thr	Gly	Val	Leu 1425	Thr	Leu	Asn
Phe	Gln 1430	Pro	Thr	Ala	Ser	Met 1435	His	ĠĴУ	Met		Glu 1440		Asp	Val
	Ala 1445		Asp	Thr		Gly 1450	Glu	Thr	Ala	Arg	Thr 1455	Glu	Val	Lys
Val.	Tyr 1460	Leu	Ile	Ser	Ąsp	Arg 1465	Asn	Arg	Val	Phe	Phe 1470	Thr	Phe	Met
Asn	Thr 1475		Glu	Glu	Val	Glu 1480		Asn	Glu	Asp	Phe 1485	Ile	Ala	Glu
Thr	Phe 1490	Thr	Leu	Phe	Phe	Gly 1495		Arg	Cys		Ile 1500		Gln	Ala
Leu	Pro 1505	Ala	Ser	Asp	Pro	Ala 1510	Thr	Gly	Ala		Arg 1515	Asp	Asp	Gln

- Thr Glu Val Arg Ala His Phe Ile Arg Asp Asp Leu Pro Val Pro 1520 1530
- Ala Glu Glu Ile Glu Gln Leu Arg Gly Asn Pro Thr Leu Val Ala 1535 1540 1545
- Thr Ile Gln Asn Ala Leu Gln Glu Glu Asn Leu Asn Leu Ala Asp 1550 1560
- Leu Phe Thr Gly Glu Thr Pro Ile Leu Gly Gly Glu Ala Gln Ala 1565 1570 1575
- Arg Ala Val Tyr Ala Leu Ala Ala Val Ala Ala Ala Leu Ala Leu 1580 1590 -
- Leu Cys Val Val Leu Leu Ile Leu Phe Phe Ile Arg Thr Arg Ala 1595 1600 1605
- Leu Asn Arg Arg Leu Glu Ala Leu Ser Met Thr Lys Tyr Ser Ser 1610 1615 1620
- Gln Asp Ser Gly Leu Asn Arg Val Gly Leu Ala Ala Pro Gly Thr 1625 1630 1635
- Asn Lys His Ala Val Glu Gly Ser Asn Pro Ile Trp Asn Glu Thr 1640 1645 1650
- Leu Lys Ala Pro Asp Phe Asp Ala Leu Ser Glu Gln Ser Tyr Asp 1655 1660 1665
- Ser Gly Leu Ile Gly Ile Glu Asp Leu Pro Gln Phe Arg Asn Asp 1670 1675 1680
- Tyr Phe Pro Pro Asp Glu Glu Ser Ser Met Arg Gly Val Val Asn 1685 1690 1695
- Glu His Met Pro Gly Ala Asn Ser Val Ala Asn His Asn Asn Asn 1700 1705 1710
- Phe Gly Phe Asn Ala Thr Pro Phe Ser Pro Glu Phe Ala Asn Ser 1715 1720 1725
- Gln Leu Arg Arg 1730

<210> 3<211> 7799<212> DNA<213> Heliothis virescens<220><221>

(1982)..(2001)<223> primer F1 primer bind<222> (4322)..(4351)<223> primer R2-<220><221> primer bind<222> <220><221> primer bind<222> (2029)..(2052)<223> primer R3 <300><308> GenBank AF367363<309> 2001-08-12<313> (1) . . (7799) < 400 > 3 gatcgactag tgaattgttg tttcaaaaaa gcaagaaatt acgtagttct aaaaataaaa 60 gtgtttttgt gtaaagtgta gtgctaaaga acttggcatt gtttgaagag gattaaaagg 120 agtecaaatt gateacaege aggtggatet accaggetag agacaegaga tacgacagag 180 tgagaactat gagatggcag tcgacgtgag aatactgacg gcagcggtat tgattctcgc 240 tgctaattta actttcgcgc aagattgttc ctatatggta gcaattccca gaccagagcg 300 accagaettt cctaatcaaa atttcgaagg agtaccatgg agtcagaacc ctctattacc 360 ageggaggat agggaagatg tgtgeatgaa egegtttgat eeaagtgeet tgaaceeegt 420 caccgtcatc ttcatggagg aggagatcga aggggacgtg gccattgcca ggcttaacta 480 ccgaggtacc aatactccga ccgtggtaac tccatttaac tttggtacct tccacttgtt 540 ggggccggtc atacgtagga tccccgagca agggggggac tggcatcttg ttattacgca 600 gaggcaggac tatgagaccc cgaacatgca gcagtatatc ttcaacgtga gggtagaaga 660 tgagececag gaagecactg tgatgeteat cattgteaae ategacgaca aegeteetat 720 gatacagatg ttcgagcctt gtgacattcc tgaacacggc gaaacgggca ccacagaatg 780 caagtccgtg gtgagcgatg ctgacggcga gatcagcaca cgtttcatga cgttcgaaat 840 cgagagcgat cgaaacgacg aagaatattt cgaacttgtc agagagaata ttcagggáca 900 gtggatgtac gtccatatga ggctcatcct caacaaacct ctggactatg aggaaaaccc 960 gctgcatttg tttagagtta cagctttgga ttccctaccg aacgttcata cagtgactat 1020 gatggtgcaa gtcgagaaca tagagagcag accgccgcgg tggatggaga tcttcgccgt 1080 gcagcagttc gatgagaaga cagcacaatc cttcagggtt cgagccatcg atggagacac 1140 gggaatcgat aaacctattt tctataggat cgaaactgaa gaaagcgaga aagatctgtt 1200 cagtgttgaa acaatagggg ctggtcggga aggtgcttgg tttaaagtcg ctccaataga 1260 cagagacacc cttgaaaagg aagttttcca cgtgtctcta attgcgtaca aatatggcga 1320 taatgacgtg gaaggaagtc cgtcatttga gtcgaaaacc gatatcgtca tcattgtgaa 1380 cgacgtgaat gatcaggcgc cggtgccttt ccgtccgtca tacttcattg aaatcatgga 1440 ggaaactgcg atgacactta atttggaaga ctttggtttc cacgatagag atcttggtcc ... 1500 gcacgcgcag tacacagtgc acctggagag catccacccg gcgggagcgc acgaggcgtt 1560 ctacatcgcg ccggaggtgg gctaccageg acagtccttc atcgtcggca cgcagaacca 1620

tcacatgctc gacttcgaag tgccagagtt ccagaagata caacttaggg tggtagccat 1680 agacatggac gatccgaggt gggttggtat cgcgattata aacattaacc tgatcaactg 1740 gaacgatgag ctgccgatct tcgagcacga tgtgcagact gtcaccttca aggagacgga 1800 gggcgctggc ttccgtgtcg ccactgtact ggctaaggac cgggatattg atgatagagt 1860 cgaacactct ctaatgggca acgcagtcaa ctacctgagt atcgacaaag acaccggcga 1920 catcctcgtg acaatcgacg atgcattcaa ctatcacaga caaaacgagc tctttgtgca 1980 gatacgaget gacgacacge tgggagagee gtacaacace aacactgeet gttccggact 2040 gtcacatcgc gccggcctat gaggtcgcgc cagcacacgt catcgtgcgc cccacctaag 2100 ctgggccctc accatacgcc ggaccccgg acactcgctc agcgaccccg gtcgcgcata 2160 cacgaccgca cgggcaacgc gcgattttct cttgtacata cttcaataca gtcttctttg 2220 caaatcgaag tttcattgaa ccgccgagac catcatccta catctggacc tcggcgctca 2280 agcattggtc cctcgcaaga actgaaccga acaggagaag tcgtcttgca agctgcgcaa 2340 2400 tggaggacta gtggggacgt gtctacccgg aaggaaggaa catactgagt gagtccgttc 2460 cgatatccct ttgaattcct gtcgttattc ccttgtatcc aggaatccag gaatttaaag 2520 ggcttcttac attgatcagg catattgatc tcttcataca tcttatttct tacgcttacg 2580 tactaaattc ataaatctat aaacttttgc acataagttc gttatctttt aaacagtaga 2640 ttctttgttc atttgcatta cgtaaacaag ctcattagcg agcggcttag cgaaccggtt 2700 tctaaacccg gtcgttcgct tcgaatcagc tgattcattg tcacttgcct atttaaacat 2760 2820 cacgtttgct ttcttgctta aagtatggct gatgcaacgt tggaggaact tcttagaggg 2880 cgtggtaatt tcgaagccga gcttggacgt ttcgataact ttttaaattc gttaacaagt 2940 ccatatttag acagtgctca tatggctaca ttgcagtctc gaattagttt tatattggca 3000 ctttatgatg acttcgacat gtttcagacg gagttggagg tgttgtcgga gaacgtcgac 3060 gacatgttgg tcgagcggga gcgtatcgag tcgcggtact tcgcactggt ggcgcgtgcg 3120 aagttcaccc ttaaacacgg gcgtgcgtca tcacctgcgg tcttgcctgc acttcctgtt 3180 gaagacgtcc ggcagcacgg ctctgactgc gggcacggcc tggttcagct gccagagatg 3240 gacttgagct gcatacette tgagaceagt accgggatte ttgcateteg gggggtgaag 3300 gctgattcca tcagctcgtc cactctttgg cggtcaggtt gtacacagta cacaaccacg 3360 tcatcaaatt cagtacatac aacatctatt acgtatatta ataatgaatt ggcacacaac 3420

4.00 30 00 1

WO 02/074079 PCT/US02/07872 18/22

aacaacaatt	ccatttcatt	aataaaccaa	aaaacatctg	aaccacatgc	agaatcatca	3486
cataacctca	tattacagac	cttctcatca	cacataatat	atcactcaaa	tacatacttt	3540
acgatgccat	gcatcaaaga	tataccattg	cctttgatac	attggctgca	ttacacgagc	3600
aaactacgtt	acacattgtc	aagcgttttg	tgctctgcag	ccggagccgt	gcttctggag	3660
ctggtacccg	tgtttcttgc	gccttcagcc	agttatccgg	actgacgcgc	gtactccgac	3720
aacagctgct	tctttttct	ttgcattttc	ctttttcac	ccttttcatg	atgagatcac	3780
tttgctatgg	tcaggttaga	ggcttgctta	aattccatac	cttctccctc	tacccatctg	3840
acctctctca	tctttccca	gacacatcca	tatcggacgg	ccactcatgt	gtacctttca	3900
ccggcagatc	actaacccac	ctcttctgtg	gctgtcacca	gtgactactg	cctccatcaa	3960
cgcagaccag	agaggcgtca	ccacaccatc	atcatcatca	tcttgaagcc	ttgacaggct	4020
tcaacccggg	gaatatgttc	cggactgtca	catcgcgccg	gcctatgagg	tcgcgccagc	4080
acacgtcatc	gtgcgccca	cctaagctgg	gccctcacca	tacgccggac	ccccggacac	4140
tcgctcatcg	accccggtcg	cgcatacacg	accgcacgcg	caacgcgcga	tctactcttg	4200
tcacctatct	ataatacagt	cttctacttt	gaacatcgaa	gttttattga	aacgccgaga	4260
ccagcaacct	acacctgcac	ctcggcgctc	aaacactgcc	caactggtga	tacagetgea	4320
agacatcaac	aacacacctc	ctacgctcag	actgcccgc	acgaccccgt	cagtggaaga	4380
gaacgtgccg	gacgggttcg	tgatccccac	cgagctgcac	gcctccgacc	ccgacaccac	4440
cgccgagctg	cgcttcagca	tcgactggga	cacttcctac	gccaccaagc	agggcaggga	4500
tgctgatgct	aaggagtttg	ttaattgtat	agaaatcgag	acggtatacc	cgaacttgaa	4560
cgaccgaggc	accgccatcg	gccgcgtggt	ggttcgcgag	atccgggaac	acgteactat	4620
agactacgag	atgttcgggg	tgctgtacct	cacagtcagg	gtcacggatc	tcaacacggt	4680
cattggagac	gactatgata	tatcaacatt	cacaatcata	ataatagaca	tgaacgacaa	4740
ccctccgctg	tgggtggaag	gcactctgac	gcaggagttc	cgcgtgcgag	aggtcgccgc	4800
ctcaggagtt	attataggat	ccgtactcgc	taccgatatc	gacggacctc	cttataatca	4860
agtgcggtat	accatcactc	ctagactgga	cactccagaa	gacctagtgg	agatcgactt	4920
caattegggt	cagatctcag	tgaagaagca	ccaggctatc	gacgcggacg	ageegeegeg	4980
ccagcacctc	tactacaccg	tggtcgccag	cgacaagtgc	gacctgctct	ctgtcgacgt	5040
gtgtccgcct	gatcctaact	acttcaacac	gcccggagag	ataacgatcc	acataacaga	5100
cacgaacaat	aaggtgcctc	gagtggaaga	ggacaagttc	gaggaaactg	tctatatcta	5160
cgagggcgcg	gaggacggag	aacacgtcgt	gcaactcttc	gccagcgatc	tggatagaga	5220
tgaaatctac	cacaaagtga	gctaccagat-	caactacgcg-	atcaaccctc	gtctccgcga	5280

·. ·..

				•		-
cttcttcgag	gtagacttgg	agaccggcct	ggtgtacgtc	aacaacactg	ccggggagaa	5340
actcgacaga	gacggcgatg	aacccacgca	tcggatcttc	ttcaacgtca	tcgataactt-	5400
ctatggagaa	ggagatggca	accggaatca	ggacgagaca	caagtgttgg	tggtgctgtt	5460
ggacatcaac	gacaactacc	cggaactgcc	tgagggtctc	tcatgggata	tctctgaggg	5520
cttgctacag	ggtgtccgtg	taaccccaga	tatcttcgcc	ccggaccgcg	acgagecegg	5580
caccgacaac	tcccgcgtgg	cgtacgacat	cgtcagcctc	acgcccaccg	acagggacat	5640
cacacttcct	caactcttca	ccatgatcac	catagagaag	gacaggggca	tcgaccagac	5700
tggagagctg	gagaccgcta	tggatttaag	aggctattgg	ggcacttatg	aagtacatgt	5760
caaggcatac	gaccatggag	ttcctcaaag	gatatcctac	gagaagtacc	cgctagttat	5820
aagaccttac	aacctccacg	accctgtgtt	cgtgttccct	caacctggaa	tgactatcag	5880
actcgcggag	gagcgagcag	tagtgaacgg	cgtgctggcg	acagtggacg	gcgagttcct	5940
cgagcgaatc	gtcgccaccg	acgaggatgg	cttacacgct	ggagttgtta	ccttctctat	6000
ctctggagat	gaggaggcgt	tgcagtactt	cgacgtgttt	aacgacggag	tgaacttagg	6060
tgcgctgacc	atcacgcagc	tcttccctga	agacttccga	gagtttcagg	tgacgattcg	6120
tgctacggat	ggtggtacgg	agccaggtcc	aagaagtacg	gactgcacgg	tcaccgtagt	6180
gtttgttcct	acgcagggag	agcctgtgtt	cgagactagc	acctacacgg	tcgcttttat	6240
tgagaaagac	gctggtatgg	aagagcgggc	cacgctgcct	ctcgccaagg	acccgcgtaa	6300
cataatgtgt	gaagatgatt	gtcacgacac	ttattacagc	attgttggag	gcaactcgat	6360
gggccacttc	gcagtagacc	cccagtccaa	cgagctgttc	ctgctgacgc	cgctggagcg	6420
cgcggagcag	gagacgcaca	ccctcatcat	cggcgccagc	gactcgccca	geceggeege	6480
cgtgctgcag	gcttccaccc	tcactgttac	tgtcaatgtt	cgagaagcaa	acccgcggcc	6540
agtgttccag	agcgctctgt	acacageegg	catctccacc	ctcgacacca	tcaacagagc	6600
tctgctgacc	ttacacgcga	cccattcaga	aggcctgccc	gtgacctaca	cgctgataca	6660
agactctatg	gaagctgact	ccacactgca	agctgtgcag	gagacagcct	tcaacctgaa .	6720
ccctcagact	ggagtgctga	ccctcaactt	ccagcccaca	gcatctatgc	acggcatgtt	6780
tgagttcgat	gtgatggcta	ctgatacagt	gggagagacc	gcgcgcactg	aagtgaaggt	6840
gtacctgata	tccgaccgca	acagagtgtt	cttcacgttc	atgaacacgc	tcgaagaagt	6900
cgaaccgaat	gaggatttca	tagcggaaac	atttaccctg	tttttcggca	tgcggtgcaa	6960
catcgaccag	acgctgcccg	ccagcgaccc	cgccaccggc	gccgccaggg	acgaccagac	7020
cgaagtcagg	gcacacttca	tacgcgacga	cctgcctgta	ccggctgagg	agattgaaca	7080

20/22 gttgcgcggt aatccaacac tagtggcgac aatccagaac gccctgcagg aggagaacct 7140 gaacctagcc gacctgttca cgggcgagac teccatectg ggcggcgagg cgcaggcgcg 7200 ggcggtgtac gcgctggcgg cggtggcggc cgcgctcgcg ctgctctgtg tcgtactgct 7260 tatactette tteateagga ctagggeect caacegtegt etggaagete tetecatgae 7320 caagtacagt teccaagaet egggtetgaa eegegtgggt etggeggege egggeaceaa 7380 caagcacgcg gtggagggct ccaacccaat ctggaacgaa accctcaagg caccggactt 7440 tgatgetett agegageagt egtaegaete ggatetgate ggeategaag aettgeegea 7500 gttcaggaac gactacttcc cgcctgacga ggagagctcc atgcggggag tcgtcaatga 7560 acacatgeet ggagetaatt cagtageaaa eeataacaat aaettegggt teaacgetae 7620 ccccttcagc ccagagttcg cgaactcgca gctcagaaga taaaatatta tagtattttt 7680 ttatataata ttatgtaaaa gtgatataac gcacactaaa atttacctat aagtatatat 7740 tgaagtgtaa gatactcgta ttatgtaaga gcatttattt ttttactacc agacagtaa 7799 <210> DNA<213> Heliothis virescens<400> tgttccggac tgtcacatcg cgccggccta tgaggtcgcg ccagcacacg tcatcgtgcg 60 ccccacctaa gctgggccct caccatacgc cggacccccg gacactcgct cagcgacccc 120 ggtcgcgcat acacgaccgc acgggcaacg cgcgattttc tcttgtacat acttcaatac 180 agtettettt geaaategaa gttteattga acegeegaga eeateateet acatetggae 240 ctcggcgctc aagcattggt ccctcgcaag aactgaaccg aacaggagaa gtcgtcttgc 300 aagetgegea acegeeegtg gaetttggae tggteaceeg eetetgegae ttaegegteg 360 tcatcgcatc gtggaggact agtggggacg tgtctacccg gaaggaagga acatactgag 420 tgagtccgtt ccgatatccc tttgaattcc tgtcgttatt cccttgtatc caggaatcca 480 ggaatttaaa gggcttctta cattgatcag gcatattgat ctcttcatac atcttatttc 540 ttacgcttac gtactaaatt cataaatcta taaacttttg cacataagtt cgttatcttt 600 taaacagtag attctttgtt catttgcatt acgtaaacaa gctcattagc gagcggctta 660 gegaaceggt ttetaaacee ggtegttege ttegaateag etgatteatt gteacttgee 720 tatttaaaca ttttatttca tatttaacgt ttttttcttt gtttgtttat tttatttat 780 tttcattctt ccacgtttgc tttcttgctt aaagtatggc tgatgcaacg ttggaggaac 840 ttcttagagg gcgtggtaat ttcgaagccg agcttggacg tttcgataac tttttaaatt 900 cgttaacaag tccatattta gacagtgctc atatggctac attgcagtct cgaattagtt 960 ttatattggc actttatgat gacttcgaca tgtttcagac ggagttggag gtgttgtcgg 1020 agaacgtcga cgacatgttg gtcgagcggg agcgtatcga gtcgcggtac ttcgcactgg 1080

•				The second second		
tggcgcgtgc	gaagttcacc	cttaaacacg	ggcgtgcgtc	atcacctgcg	gtcttgcctg	1140
cacttcctgt	tgaagacgtc	cggcagcacg	gctctgactg	cgggcacggc	ctggttcage-	1200
tgccagagat	ggacttgagc	tgcatacctt	ctgagaccag	taccgggatt	cttgcatctc	1260
ggggggtgaa	ggctgattcc	atcagctcgt	ccactctttg	gcggtcaggt	tgtacacagt	1320
acacaaccac	gtcatcaaat	tcagtacata	caacatctat	tacgtatatt	aataatgaat	1380
tggcacacaa	caacaacaat	tccatttcat	taataaacca	aaaaacatct	gaaccacatg	1440
cagaatcatc	acataacctc	atattacaga	ccttctcatc	acacataata	tatcactcaa ·	1500
atacatactt	tacgatgcca	tgcatcaaag	atataccatt	gcctttgata	cattggctgc	1560
attacacgag	caaactacgt	tacacattgt	caagcgtttt	gtgctctgca	gccggagccg	1620
tgcttctgga	gctggtaccc	gtgtttcttg	cgccttcagc	cagttatccg	gactgacgcg	1680
cgtactccga	caacagctgc	ttctttttc	tttgcatttt	cctttttca	cccttttcat	1740
gatgagatca	ctttgctatg	gtcaggttag	aggcttgctt	aaattccata	ccttctccct	1800
ctacccatct	gacctctctc	atcttttccc	agacacatcc	atatcggacg	gccactcatg	1860
tgtacctttc	accggcagat	cactaaccca	cctcttctgt	ggctgtcacc	agtgactact	1920
gcctccatca	acgcagacca	gagaggcgtc	accacaccat	catcatcatc	atcttgaagc	1980
cttgacaggc	ttcaacccgg	ggaatatgtt	ccggactgtc	acatcgcgcc	ggcctatgag	2040
gtcgcgccag	cacacgtcat	cgtgcgcccc	acctaagctg	ggccctcacc	atacgccgga	2100
ccccggaca	ctcgctcatc	gaccccggtc	gcgcatacac	gaccgcacgc	gcaacgcgcg	2160
atctactctt	gtcacctatc	tataatacag	tcttctactt	tgaacatcga	agttttattg	2220
aaacgccgag	accagcaacc	tacacctgca	cctcggcgct	caa		2263
<210> 5<21	1> 252<212). DWA-212.	77-7 3 1- 3			
		cgccggccta		virescens<		60
ccccacctaa	gctgggccct	caccatacge	cggacccccg	gacactcgct	cagcgacccc	120
ggtcgcgcat	acacgaccgc	acgggcaacg	cgcgattttc	tcttgtacat	acttcaatac	180
agtcttcttt	gcaaatcgaa	gtttcattga ·	accgccgaga	ccatcatcct	acatctggac	240
cteggegete	aa 					252
<210> 6<21	1. 255.010					•
tgttccggac	tgtcacatcg	> DNA<213> cgccggccta	нетіотhіs tgaggtcgcg	virescens< ccagcacacg	400> 6 tcatcgtgcg	60
		caccatacgc				120
ggtcgcgcat	acacgaccgc	acgcgcaacg	cgcgatctac	tcttgtcacc	tatctataat	180

acagtettet actttgaaca tegaagtttt	attgaaacgc cgagaccagc aacctacacc	240
tgcacctcgg cgctcaa	and the second s	257
<210> 7<211> 26<212> DNA<213> atacgagetg acgacaeget gggaga	Heliothis virescens<400> 7	26
<210> 8<211> 30<212> DNA<213> tctgagcgta ggaggtgtgt tgttgatgtc	Heliothis virescens<400> 8	30
<210> 9<211> 24<212> DNA<213> gcgcgatgtg acagtccgga acag	Heliothis virescens<400> 9	24

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 26 September 2002 (26.09.2002)

PCT

(10) International Publication Number WO 02/074079 A3

- (51) International Patent Classification⁷: C12P 19/34, C07H 21/04
- C12Q 1/68,
- (21) International Application Number: PCT/US02/07872
- (22) International Filing Date: 15 March 2002 (15.03.2002)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/276,180

15 March 2001 (15.03.2001) US

- (71) Applicant (for all designated States except US): CLEM-SON UNIVERSITY [US/US]; Office of Technology Transfer, 300 Brackett Hall, Box 345702, Clemson, SC 29634-5702 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HECKEL, David, G. [US/AU]; 8/101 Palmerston Street, Carlton, VIC 3053 (AU). GAHAN, Linda, J. [US/US]; 101 Martin Street, Clemson, SC 29631-1526 (US).
- (74) Agent: MULLINAX, J., Bennett; Dority & Manning, P.A., P.O. Box 1449, Greenville, SC 29602-1449 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE; IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report:
 19 December 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

9

(54) Title: POLYNUCLEOTIDE ENCODING A GENE CONFERRING RESISTANCE TO BACILLUS THURINGIENSIS TOXINS

(57) Abstract: Nucleic acid (DNA) probes are provided which will specifically identify a gene for resistance of Bt in insect populations. Sequences are identified associated with the onset of resistance to *Bacillus thuringiensis* toxins. The sequences are used as probes to monitor the presence of acquired insect resistance associated with transgenic crops.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/07872

A. CLASSIFICATION OF SUBJECT MATTER								
IPC(7) US CL	: C12Q 1/68; C12P 19/34; C07H 21/04 : 435/6, 91.2; 536/23.1							
According to International Patent Classification (IPC) or to both national classification and IPC								
	B. FIELDS SEARCHED							
	cumentation searched (classification system followed	by classification symbols)						
U.S. : 4.	35/6, 91.2; 536/23.1							
Documentation	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched							
	<u> </u>							
	ta base consulted during the international search (namontinuation Sheet	ne of data base and, where practicable, so	earch terms used)					
			- *					
	UMENTS CONSIDERED TO BE RELEVANT							
Category *	Citation of document, with indication, where ap		Relevant to claim No.					
Х, Р	GAHAN et al., Identification of a gene associated w virescens. Science. 03 August 2001, Vol. 293, No. document, especially page 859.		15					
	LIC 5 602 401 A (DILLI A at al) 02 December 1007	(00.12.1007) can entire reference	15					
A	US 5,693,491 A (BULLA et al) 02 December 1997 especially column 3, line 39-column 4, line 25.	(02.12.1997), see entire reference,	13					
A, P	NAGARAJU, J, Identification of a gene associated		15					
	pest, Heliothis virescens and its implications in Bt to							
	Science. 10 October 2001, Vol. 81, No. 7, pages 7	46-747, see entire reference.						
			1					
	•							
		•	:]					
			·					
	_		. 1					
	i de la companya de							
Purther	r documents are listed in the continuation of Box C.	See patent family annex.						
• 5	pecial categories of cited documents:	"T" later document published after the inte date and not in conflict with the applie	emational filing date or priority					
	t defining the general state of the art which is not considered to be plar relevance	principle or theory underlying the inv	ention					
	oplication or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be conside when the document is taken alone						
"L" document establish specified	t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"Y" document of particular relevance; the	claimed invention cannot be					
specified) considered to involve an inventive step when the document is combined with one or more other such documents, such combine "O" document referring to an oral disclosure, use, exhibition or other means being obvious to a person skilled in the art								
	actual completion of the international search	Date of mailing of the international services 18 SEP	arch report ZUUZ					
	002 (01.08.2002)	Authorized officer 12 and 12						
1	nailing address of the ISA/US missioner of Patents and Trademarks	Valene Soll - 7	assofn					
Boo	t PCT shington, D.C. 20231	Diana B. Johannsen						
1	o. (703)305-3230	Telephone No. 703/308-0196						
	Form PCT/ISA/210 (second sheet) (July 1998)							

INTERNATIONAL SEARCH REPORT

PCT/US02/07872

Continuation of Box I Reason 2:

10 ,

The computer readable form of the Sequence Listing contained errors. No meaningful search of claims 1-14 could be conducted without a sequence search. It is noted that claim 15 was searched to the extent possible using a text search (no sequence search could be conducted).

Continuation of B. FIELDS SEARCHED Item 3:

USPT, DWPI, Agricola, Medline, Biosis, Embase, CAPlus, Lifesci, Scisearch search terms: HevCaLP, Btr4, Btr1, cadherin, BT, B. thuringiensis, resistan###; inventors' names; Nagaraju, J.

Form PCT/ISA/210 (second sheet) (July 1998)

THIS PAGE BLANK (USPTO)